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Margot Brandt 
 
Rare gene-disrupting variants and common regulatory variants play key roles in rare and 
common disease, respectively. These variants are of great interest for investigation into genetic 
contributions to disease, but experimental methods to validate their impact on gene expression 
levels are lacking. In this study, we utilized CRISPR/Cas9 genome editing to validate regulatory 
variants including cis-eQTLs, rare stop-gained variants in healthy and disease cases and one 
immune-response trans-eQTL master regulator. 
For investigation into common and rare regulatory variants within transcribed regions, we 
developed a scalable CRISPR-based polyclonal assay for experimental assessment. First, we 
applied this assay to nine rare stop-gained variants found in the general population, in GTEx. After 
editing, the stop-gained variants show a significant allele-specific depletion in transcript 
abundance, as expected. Next, we utilized the assay to validate 33 common eQTLs found in GTEx. 
After editing, the eQTL variants show higher variance in effect size than control variants, 
indicating a regulatory effect. Finally, we applied the polyclonal editing approach to clinical and 
new stop-gained variants in two disease-associated genes. The results follow the expected trend, 
with NMD being triggered by variants upstream of the NMD threshold but not by those beyond. 
This method demonstrates scalable experimental confirmation of putative causal regulatory 
variants, and improved interpretation of regulatory variation in humans. 
Next, we sought to experimentally validate an immune-response eQTL for IRF1 in cis and 
many genes in trans under LPS stimulation. We used CRISPRi to repress the enhancer locus and 
   
 
found that the enhancer is active in our immune cell system. Next, we used CRISPR-Cas9 genome 
editing and isolation of monoclonal cell lines to target this variant locus. After LPS stimulation, 
we performed RNA-sequencing on wild type and edited clones, showing that the effect size of the 
genes which are associated with the trans-eQTL are correlated with differential expression 
between the edited and wild type cell lines for the same genes. Additionally, we find that the 
differential expression between edited clones is correlated with CRISPRi repression of the IRF1 
promoter and enhancer. In this way, we were able to identify a common genetic variant which 
modifies the transcriptomic immune response to LPS and validate the trans-eQTL signal.
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Chapter 1: Introduction 
I. Genetic variation and human traits 
 Genetic variation in the genome is ubiquitous and diverse. Investigating genetic variation 
can provide insights into disease etiology, phenotypic variation, gene function, evolution, and 
more. Variants can be broadly classified into four categories: structural variants, tandem repeat 
variants, single nucleotide variants (SNV), and small insertion/deletion variants (indel). Structural 
variants cause genomic rearrangements or copy number variants of greater than 50 bp. They can 
have severe consequences and are quite rare, occurring several thousand times per human genome. 
Tandem repeat variants are variants which affect the number of repeats in a repetitive region of 
the genome. Due to the difficulty in sequencing and mapping these repetitive regions, the exact 
frequency is unknown. SNVs and indels are by far the most common form of variation with 3-4 
million SNVs and 0.4-0.5 million indels occurring per human genome.  
SNVs and indels can be further classified as coding or noncoding. The protein-coding 
portion of the genome is composed of the segments of genomic DNA which translate to the protein 
sequence of the roughly 20,000 proteins encoded in the genome. Coding variants are defined as 
those falling into this protein-coding portion of the genome, while noncoding variants fall into the 
99% of the genome which does not code for protein. The vast majority of SNVs and indels have 
no functional effect, but many do. Noncoding variants have typically been thought of as having an 
effect on the dosage of protein, while coding variants are thought of as affecting protein structure 
by changing the protein coding sequence. As we study more of these variants, we find that both 
coding and noncoding variants can impact dosage or structure through a variety of mechanisms 
(figure 1-1). 
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Figure 1-1. Different types of genetic variants and their potential effects on protein production in the 
cell.  
Non-coding variants can impact dosage or structure of protein or have no effect, whereas coding variants 
can affect dosage, structure or have no effect at all. Adapted from (Lappalainen et al., 2019). 
 
Understanding phenotypic consequences of variation of the genome has been a priority in 
the field of genetics for as long as the field has existed. Variants associated with mendelian 
disorders tend to be rare and have high penetrance. Historically, linkage analysis was utilized to 
identify the location of mendelian variants by tracking disease cases in families. In the age of next 
generation sequencing, these variants can be discovered by whole exome sequencing of unrelated 
patients to look for damaging mutations within the coding region of genes. However, a challenge 
to this approach is distinguishing harmless variants from gene-disrupting.  
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Common variants which typically have low penetrance and have small contributions to 
disease require a much larger sample size to detect their effects. The current standard approach to 
understand the effects of common variants is associating variants in the human population with 
human traits through genome-wide association studies (GWAS). GWAS have been performed on 
a multitude of complex human traits (Welter et al., 2014). Not surprisingly, the traits being studied 
by GWAS with the most interest and attention are human diseases. The rationale behind GWAS 
design is that alleles which are enriched in disease subjects over controls are likely to be 
contributing to disease. A variant which is found to be associated with disease would ideally have 
a clear mechanism of effect on a gene, e.g. by disrupting the protein-coding sequence of a gene by 
introduction of a missense or premature stop codon or by affecting splicing. Unfortunately, about 
90% of GWAS variants are not found within protein-coding regions but instead within the 
noncoding portion of the genome (Maurano et al., 2012). This phenomenon has created a need for 
a better understanding of how noncoding variants affect genome function, regulation of proximal 
target genes, and subsequent pathways that affect disease risk.  
A cis-regulatory variant in the genome is defined by one allele causing a higher expression 
of a proximal gene than the other allele (figure 1-2a). Noncoding regulatory variants can affect 
expression of genes through a multitude of mechanisms. For example, they can act by disrupting 
the binding site of a transcription factor (TF) in an enhancer or affecting the chromatin state of the 
region surrounding the variant. One obstacle is determining which gene a variant is affecting. 
Assuming that the variant affects the nearest gene is a flawed approach since it has been reported 
that approximately one-third of enhancers affect genes which are not the nearest (Gasperini et al., 
2019) and up to two-thirds of GWAS variants are associated with a gene which is not the nearest 
(Zhu et al., 2016). An understanding of the effect of an associated variant on gene expression gives 
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the first clue into the mechanism of disease. Further experimental follow up can deduce how this 
expression regulation then affects the cell or organism but the first step is to understand how the 
sequence modification affects gene expression. Thus, systematic interrogation of the effects of 
common variants on gene expression is essential. Expression quantitative trait loci (eQTL) studies 
have emerged to fill this void, associating variants with expression transcriptome-wide in order to 
identify regulatory variants.  
II. Discovering common regulatory variants 
Expression quantitative trait loci (eQTL) studies 
eQTL studies aim to identify common regulatory variants which have an effect on the 
transcriptome. A cis-eQTL study is designed to detect regulatory variants that affect the expression 
of genes nearby the variant. The studies are typically designed so that genotype data, either from 
genotyping arrays or whole genome sequencing, and gene expression data, either from microarray 
or RNA-sequencing, are collected for a population of individuals. To test for association of a 
variant with expression of a proximal gene, a linear regression is performed between the genotype 
of the variant and expression of the gene (figure 1-2b).  This test is repeated for all variants within 
a specific window on either side of the transcription start site (TSS) of the gene, resulting in a p-
value of association for each variant (figure 1-2c). This is then repeated for every gene in the 
genome. A gene which is associated with a significant eQTL is referred to as an eGene, while all 
variants that are significantly associated with the eGene are referred to as eVariants. With large 
enough sample sizes, eQTL studies have discovered an eQTL association for almost every gene in 
the genome, and multiple independent eQTLs for many genes (GTEx Consortium et al., 2017). 
The results help illuminate elements in the genome that regulate gene expression, as well as assist 
in understanding the mechanisms of human disease.  eQTLs have been reported to be enriched for 
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GWAS loci (Lappalainen et al., 2013) and GWAS loci that are also eQTLs are more likely to be 
true associations (Nicolae et al., 2010). Overlap between eQTLs and GWAS loci is therefore 
utilized to interpret the mechanism of noncoding GWAS variants (Zhu et al., 2016).  
 
Figure 1-2. An example eQTL.  
a) The A allele results in higher expression of the AGA gene than the G allele. Individuals homozygous for 
the G allele have the lowest overall expression, while those homozygous for the A allele have the highest 
expression. Heterozygous individuals have intermediate expression. b) The effect of the variant is detected 
by performing a linear regression between genotype and expression across all individuals in the study. This 
test is repeated for all variants within 1 Mb of the transcription start site of AGA. c) The top variant has the 
strongest association with gene expression, but many variants may have significant associations due to 
linkage disequilibrium with the causal variant. Adapted from (Brandt and Lappalainen, 2017). 
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Cis-eQTLs regulate expression in an allelic fashion, meaning that the variant affects 
expression only of the haplotype of the gene on which it falls. Consider an example where a TF 
binding site is disrupted by the alternative allele of the variant, resulting in decreased expression 
of the gene. The TF’s binding on the reference allele is not affected and therefore the expression 
of that haplotype remains unchanged. Trans-eQTL studies, on the other hand, aim to detect 
regulatory variants that act on distal genes. As in cis-eQTL studies, variants are tested for 
association using linear regression between genotype and expression. A trans-eQTL is defined as 
an association between a variant and a gene which is enacted through a trans mediator. Trans-
eQTLs in practice are detected as a variant which resides on a different chromosome or greater 
than 5 Mb from the TSS of the eGene.  
One possible mechanism through which a trans-eQTL can act is by affecting the expression 
of another gene in cis, which then affects the expression of the tested gene (example in figure 1-
3). Thus, the causal variant for a cis-eQTL can also be the causal variant for a trans-eQTL. This is 
not the only mechanism through which a trans-eQTL can act. In addition to the cis-eGene directly 
regulating the trans-eGene, it could regulate another gene which in turn regulates the trans-eGene. 
Additionally, a trans-eQTL might not involve a cis-eQTL at all. A variant in the protein-coding 
region of a TF gene affecting its activity could in turn affect expression of any downstream targets 
of that gene. Trans-eQTLs by nature do not exert an allelic effect. As in the example in figure 1-
3, the trans-eQTL effect exists because the amount of TF A is reduced, and that affects both alleles 
of Gene B equally.  
Unlike cis-eQTL studies where variants are limited to a window around the TSS of a given 
gene, trans-eQTL studies test all variants genome-wide for association with each gene. Thus, the 
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multiple testing burden on trans-eQTLs is much higher than for cis-eQTLs, which has made them 
much more difficult to detect with the limited size of a typical eQTL study. Even studies with 
sample sizes of greater than 5,000 individuals have discovered modest numbers of trans-eQTLs, 
on the order of a couple of hundred (Brynedal et al., 2017; Westra et al., 2013; Yao et al., 2017). 
By increasing the sample size to over 31,000 and testing only trait-associated variants, a recent 
study was able to detect a few thousand trans-eQTLs (Võsa et al., 2018). Additionally, trans-eQTL 
false positives are more likely than in cis-eQTLs and can be caused by batch effects, population 
structure or even RNA-sequencing alignment errors (Saha and Battle, 2018). 
 
Figure 1-3. An example mechanism of a trans-eQTL association.  
(1) The variant is a cis-eQTL variant for Gene A, which codes for a transcription factor, TF A. (2) When 
the protein TF A is translated from Gene A, it in turn affects expression of Gene B. (3) Thus, the variant 
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Context-specificity of eQTLs 
Most of the eQTL studies mentioned thus far have performed RNA-seq on either one type 
of cell line isolated from individuals or an easily accessible tissue, such as whole blood. Recently, 
emphasis has been placed on context-specific eQTLs: either tissue-specific or condition-specific. 
For example, the GTEx consortium has performed eQTL analysis on 44 tissues from hundreds of 
post-mortem donors (GTEx Consortium et al., 2017). The resulting eQTLs demonstrate a u-shaped 
distribution where eQTLs tend to be either shared by all tissues or unique to one tissue. 
Interestingly, it appears that trans-eQTLs tend to be more tissue-specific than cis-eQTLs.  
In addition to tissue-specific eQTLs, studies have focused on eQTLs which are active under 
specific conditions. Innate immune cells, such as monocytes, have been used for looking at 
context-specificity of eQTLs under stimulation (Chen et al., 2016; Fairfax et al., 2014; Kim-
Hellmuth et al., 2017). Monocytes lend themselves to this type of study because they can be 
isolated from blood and have a transcriptional response to exposure to viral or bacterial stimuli. 
Immune-response eQTLs (reQTL) are eQTLs where the association between the variant and 
eGene varies based on stimulation.  Figure 1-4 shows an example of a reQTL where a variant is 
not associated with expression of a gene under normal baseline conditions, but with exposure to a 
stimulus, individuals with the A allele have higher gene expression of the eGene than those with 
the G allele. Immune reQTLs have been found to overlap GWAS signals for diseases related to 
infection and immunity (Chen et al., 2016; Fairfax et al., 2014; Kim-Hellmuth et al., 2017). This 
demonstrates the utility of immune reQTLs to help determine the mechanism of GWAS loci in the 
noncoding genome, perhaps revealing mechanisms that would be missed if only utilizing cells 
without stimulation.  
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Figure 1-4. A simulated example immune-response eQTL in human immune cells. (a) Under normal 
conditions, the variant does not show an association with expression of the gene, but with immune 
stimulation (b), there is an effect of the genotype of the variant on expression of the gene. Thus, the variant 
is considered an immune-reQTL. 
 
Linkage disequilibrium in eQTL studies 
Linkage disequilibrium (LD) is the phenomenon that variants near each other on the same 
chromosome tend to be inherited together. Recombination during meiosis, which occurs more 
often at recombination hotspots, can separate variants on the same chromosome. But if there is 
little recombination between two variants, they are often found in the same individuals and are 
therefore difficult to statistically disentangle in association studies. LD is advantageous in 
association studies where variants which are not directly measured are imputed, but it is a problem 
for identifying the causal variant at an eQTL locus. Any variant with a significant association with 
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LD phenomenon is exemplified in figure 1-2c where several variants have highly significant p-
values for association with the AGA gene, while only one variant is likely to be causal.  
III. Approaches to determine causal variants 
Statistical fine-mapping of eQTLs 
 In order to distinguish causal variants from those in LD with causal variants, several 
computational and experimental methods have been developed. The computational methods 
generally involve statistical fine-mapping of the eQTL locus to assign a probability of causality to 
each variant (Hormozdiari et al., 2014; Pickrell, 2014; Wellcome Trust Case Control Consortium 
et al., 2012; Wen et al., 2015). The methods incorporate LD information between variants with the 
genetic association statistics to determine probability of causality, while taking into account noise 
that can be introduced by small sample sizes. Some of these methods assume a single causal variant 
at the eQTL locus (Pickrell, 2014; Wellcome Trust Case Control Consortium et al., 2012), which 
can lead to false negatives or positives. CAVIAR (Hormozdiari et al., 2014), the fine-mapping 
approach utlilized in chapter 2, provides posterior probabilities of association for each eVariant, 
without assumption of the number of eQTLs present at an eGene. Even with fine-mapping, it is 
often still unclear which is the causal variant. In instances where two variants are in perfect or 
close to perfect LD, it is impossible computationally to distinguish which is causal. Thus, the door 
is open to experimental approaches to detect causality of eVariants. 
 
Experimental approaches for validating regulatory variants 
 The high-throughput experimental approaches to validating regulatory signals fall into two 
broad categories: (1) those which focus on the difference in expression between multiple alleles of 
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a regulatory variant, incorporating the sequence into a reporter assay, and (2) those which confirm 
activity of a regulatory element within which a variant may fall, maintaining the native genomic 
context.  
The first category of high-throughput approaches is dominated by massively parallel 
reporter assays (MPRAs), reviewed in (Inoue and Ahituv, 2015; Santiago-Algarra et al., 2017). 
MPRAs consist of incorporating a potential regulatory DNA sequence into a reporter plasmid, 
upstream of a weak promoter and a reporter gene such as GFP or luciferase, often followed by a 
unique barcode which can be linked to the regulatory DNA sequence. This is done in parallel with 
thousands of DNA sequences either composed of endogenous gDNA or with mutations introduced. 
The constructs are pooled and introduced into cells in culture. To quantify the effect of each DNA 
sequence, the barcodes are sequenced from the mRNA of the cells. An over- or under-
representation of a particular barcode suggests that the matching DNA sequence in indeed 
regulatory. A comparison of the effect of two alleles of the same DNA sequence can identify an 
allele-specific effect of a variant on expression of a gene, and therefore point to a causal regulatory 
variant. The major advantage to these assays is certainly the high-throughput capacity; It has been 
extended to genome-wide scale (van Arensbergen et al., 2019). The ability to compare alleles of 
the same variant in isolation is also an advantage but taking the variant out of its endogenous 
genomic context into an artificial construct can result in false-positive or false-negative results. In 
addition, the results from these assays often do not correlate well with population trends (Tewhey 
et al., 2016; van Arensbergen et al., 2019). 
The second category of high-throughput approaches involves confirming regulatory 
elements while maintaining the native genomic context. Most recently, the emergence of CRISPR 
interference (CRISPRi) technology has led groups to utilize the technology to perturb regions of 
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the genome to detect regulatory effects on expression of genes (Gasperini et al., 2019; Gilbert et 
al., 2013; Yeo et al., 2018). The advantage to this approach is that it maintains the endogenous 
genomic context, which can be important for enhancer activity. However, these assays do not 
provide allele-specific effects and therefore cannot directly confirm the effect of a variant on 
expression of a gene.  
All above high-throughput assays, both the reporter-based and endogenous approaches, are 
relatively good at identifying regulatory elements in enhancers.  A major drawback is that they are 
unable to assay variants which are found within the transcript. These variants can affect the 
expression of genes either through stability of the transcript, splicing disruption or introduction of 
frameshift or premature stop codons. 
Introduction of a specific variant into human cells using genome editing and homologous 
recombination is another approach with which to validate single regulatory variants. CRISPR/Cas9 
genome editing, a tool harnessed from an adaptive immune system in bacteria, provides an easily-
programmable method to target a specific locus in the genome for editing (Cong et al., 2013; Jinek 
et al., 2012; Shalem et al., 2014). In practice, genome editing can be achieved by introducing Cas9 
and a locus-targeting guide RNA (gRNA) into a cell line. This induces the Cas9 enzyme to make 
a double stranded break (DSB) in the genomic DNA at the locus which the gRNA targets. In order 
to achieve a specific change in the DNA sequence, for example converting a specific variant to the 
alternative allele, a homologous template containing the variant is also provided. The cell has two 
pathways for repair of a DSB:  non-homologous end joining (NHEJ) and homology directed repair 
(HDR). The editing of the cells will yield a combination of results from both repair pathways: 
NHEJ will manifest as insertions or deletions, and HDR will manifest as a seamless repair of the 
genome using the provided template. In order to assess particular effects of the variant, generally 
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one would isolate single cells, expand each into a monoclonal cell line and select those cell lines 
which have the desired mutation. All in all, this is a fairly time consuming and low-throughput 
process, and therefore is only practical in cases where a single variant or handful of variants are of 
interest (Gupta et al., 2017; Soldner et al., 2016; Zhu et al., 2018). 
 A less labor-intensive genome editing approach involves editing cells as described above 
but analyzing the polyclonal edited cell population instead of isolating monoclonal cell lines. 
Groups have utilized this approach with CRISPR/Cas9 genome editing and homologous 
recombination followed by sequencing for allelic expression to validate the effects of rare variants 
(Li et al., 2017) and all possible mutations in a particular exon by using saturation mutagenesis 
(Findlay et al., 2014). The advantages to this approach of variant confirmation are that the 
endogenous genomic locus of the variant is maintained and the allelic effect of the variant is 
measured. This approach is limited to validation of variants within the transcript, thus providing a 
complimentary method to validate variants which are unable to be validated with the MPRA 
method. This approach takes advantage of the fact that regulatory variants within the transcript are 
transcribed in the mRNA and therefore can be quantified by sequencing the mRNA. In parallel, 
the gDNA is sequenced in order to quantify the editing efficiency. A significant difference between 
the proportion of the variant in gDNA versus mRNA suggests a regulatory effect of the variant. 
An application of this approach to confirm regulatory transcript variants genome-wide would be 
an integral contribution to the field, and one of the aims of this thesis. 
IV. Premature stop-gained variants 
Nonsense-mediated decay 
 Like common transcript regulatory variants, rare stop-gained variants often exert an allelic 
effect on the expression level of the gene in which they reside. This expression effect is mediated 
   
 14 
through the nonsense mediated decay (NMD) pathway. NMD is a quality control mechanism 
utilized by the cell to detect transcripts with premature stop codons and degrade them before they 
are translated to potentially damaging truncated proteins. The NMD pathway has been extensively 
studied (reviewed in (Hug et al., 2016)). Studies find that premature stop codons prior to 50-55 bp 
before the last exon-exon junction tend to be degraded by the NMD pathway, whereas stop codons 
beyond this cutoff tend to escape NMD (Nagy and Maquat, 1998). As transcription of a gene 
occurs in the nucleus, an exon-junction complex is applied to each pre-mRNA 20-24 bp upstream 
of each exon-exon junction. This complex remains intact through spicing and transport to the 
cytoplasm, where NMD machinery recognizes a premature stop-codon and determines whether it 
is more than 50-55 bp upstream of the last exon-exon junction. The biological rationale for this 
cutoff is that a protein with a small truncation at the 3’ end is perhaps less damaging to the cell 
than a reduction in protein levels, which would be the result from NMD.  
 In RNA-sequencing data, a heterozygous stop-gained variant which triggers NMD can be 
detected as allele-specific expression of the gene, with a depletion of the stop-gained allele (Rivas 
et al., 2015) (exemplified in figure 1-5). In a heterozygous cell where one allele of a gene contains 
a premature stop codon, both alleles are transcribed in the nucleus. Once the mRNA reaches the 
cytoplasm, NMD machinery recognizes the premature stop codon and specifically degrades those 
transcripts. When mRNA is isolated from the cell for RNA-sequencing, there is a strong 
enrichment for the wild type allele.  
 
Stop-gained variants in rare disease 
 Stop-gained variants are enriched in rare disease-causing variants (Holbrook et al., 2004). 
These variants can result in disease whether they trigger NMD or not. Variants which trigger NMD 
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can result in an up to 50% reduction in the amount of a given protein in a cell. If the gene is 
haploinsufficient, this can result in disease. On the other hand, if the stop-gained variant escapes 
NMD (which is likely if it falls after the 50-55 bp cutoff), it can result in a truncated version of the 
protein which can result in dominant negative effects of the protein which can be severe.  
For some disease-associated genes, there are stop-gained variants both at the beginning of 
the transcript, likely triggering NMD, and at the end of the transcript, likely escaping NMD. 
Depending on where the variant is within the transcript, the disease can manifest with different 
symptoms or method of inheritance (Miller and Pearce, 2014).  
 
 
Figure 1-5. Stop-gained variants trigger nonsense mediated decay, which is detected in RNA-
sequencing. A visual example of a cell which is heterozygous, with one reference allele and one stop-
gained allele. The stop-gained variant introduces a premature stop codon into the transcript. In the cell, both 
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alleles are transcribed normally, but after transcription, the NMD complex degrades the transcripts with the 
stop-gained allele. Thus, the resulting effect of the stop-gained variant is a decreased presence of the stop-
gained allele in the mRNA, which can be observed in RNA-sequencing data. 
 
V. Innate immune response to LPS 
 The innate immune system is integral to the body’s rapid response to invading pathogens. 
Cells of the innate immune system are responsible for recognizing pathogens, quickly activating a 
transcriptional response, and releasing signaling molecules to inform other cells throughout the 
body of the infection. Many immune cell-surface receptors responsible for recognizing particular 
pathogenic molecules belong to the Toll-like receptor (TLR) family. The members of the TLR 
family each recognize specific molecules characteristic of bacteria, fungi, protozoa and viruses 
(Takeda and Akira, 2005).  
Extracellular recognition of lipopolysaccharide (LPS), a cell-surface marker on gram-
negative bacteria, is transduced through the trans-membrane protein TLR4. TLR4 binds to 
extracellular LPS cooperatively with extracellular proteins CD14 and MD2 (Rosadini and Kagan, 
2017). The binding of LPS triggers dimerization of TLR4, resulting in activation of two parallel 
signaling pathways: MyD88-dependent and MyD88-independent (figure 1-6). The MyD88-
dependent pathway is responsible for inducing transcription of pro-inflammatory cytokines and 
the MyD88-independent pathway induces transcription of type-I interferons and their targets. 
Notably, both pathways act through activation of the TF NF-kB, whose targets include a broad 
array of pro-inflammatory chemokines and cytokines (Liu et al., 2017). In macrophages and 
monocytes, this release of cytokines in response to LPS stimulation is important for activating and 
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recruiting cells of the innate and adaptive immune system as well as stimulating local tissue 
inflammation (Turner et al., 2014).  
 
Figure 1-6. LPS-triggered signal transduction through the TLR4 receptor. TLR4, located on the 
surface of innate immune cells, binds LPS with cooperation from CD14 and MD-2. This binding activates 
two branches of signaling, the MyD88-dependent pathway and the My88-independent pathway mediated 
by TRIF. Both pathways activate NF-kB and induce expression of cytokines and type I interferons. Adapted 
from (Lu et al., 2008). 
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VI. Interferon-regulatory factor 1 
 Interferon-regulatory factor 1 (IRF1) is a member of a family of nine IRF transcription 
factors. The IRF TFs were first discovered for their regulation of expression of type I interferon 
genes and they recognize variations on the interferon-stimulated response element in the genome. 
In addition to interferon regulation, IRFs are involved in many facets of innate and adaptive 
immunity, oncogenesis and metabolism (Honda and Taniguchi, 2006; Tamura et al., 2008; Zhao 
et al., 2015).  
IRF1 was the first member of the IRF family to be identified and was originally shown to 
be necessary for type-I interferon induction upon viral stimulation (Matsuyama et al., 1993). In 
addition, it has been implicated in lymphoid and myeloid lineage development, with abnormalities 
in immune cell development observed in irf1 knockout mice (Abdollahi et al., 1991; Matsuyama 
et al., 1993; Ogasawara et al., 1998). IRF1 has additionally been shown to be involved in activation 
of macrophages via the IFN-g receptor (Langlais et al., 2016). Also in macrophages, IRF1 has been 
shown to be essential for induction of inducible nitric oxide synthase (iNOS), which produces 
nitric oxide, an important cell signaling molecule released by innate immune cells in response to 
infection (Kamijo et al., 1994).  In the same study, irf1 knockout mice were shown to be more 
susceptible to infection with mycobacterium. Another study showed that IRF1-deficient 
macrophages have reduced IL-12 cytokine induction after stimulation with LPS (Liu et al., 2003). 
Taken together, past research suggests an important role for IRF1 in inducing immune-response 
genes in response to infection. 
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IRF1 is thought to be a target of NF-kB due to conserved NF-kB TF binding sites in its 
promoter (Harada et al., 1994; Iwanaszko and Kimmel, 2015). Additionally, IRF1 is strongly 
induced after stimulation with LPS in monocytes (Kim-Hellmuth et al., 2017). Taken together with 
the fact that NF-KB is a major signal transducer upon TLR4 activation, it is possible that IRF1 
transcription is induced by LPS via NF-kB regulation. Additionally, IRF1 is further implicated in 
TLR signaling, through direct activation by MyD88 (Negishi et al., 2006). Altogether, there is 
plausibility for IRF1 being involved in TLR4 signaling through induction by NF-KB and activation 
by MyD88. This connection is further bolstered by the finding that irf1 knockout mice have 
decreased survival after infection with LPS (Pan et al., 2013), implicating IRF1 in LPS signaling. 
However, the specific role IRF1 plays in LPS signaling has yet to be revealed.  
VII. Summary and thesis aims 
 In genetic association studies, such as eQTL mapping or GWAS, it is not always clear 
whether an associated variant is causal or linked to a causal variant through LD. Computational 
methods to identify causal variants, such as various fine-mapping approaches, can improve our 
estimation of causality, but fall short in cases of high LD and provide probabilistic estimates rather 
than empirical evidence. Therefore, experimental methods to validate causal regulatory variants 
are essential. MPRA approaches attempt to validate these variants in high throughput, but in doing 
so remove the variants from their endogenous loci, and cannot address variants within the 
transcript. In studies of rare stop-gained variants, there is often a strong hypothesis for the 
mechanism of the causal variant, but since the variant is often observed in only one or few 
individuals, statistical evidence is difficult to obtain from the extremely small sample size. This 
makes it difficult to establish the functional mechanism without experimental approaches. 
   
 20 
In this thesis, we aimed to validate and characterize regulatory variants found in the human 
population using CRISPR/Cas9 genome editing. In chapter 2, we first focused on transcript 
variants from the general population which are associated with gene expression. This includes rare 
stop-gained variants which are suspected to act through the NMD pathway, and common eQTL 
variants which lie in the transcript. Next, we tested our ability to validate the effects of disease-
causing regulatory variants, focusing on premature stop-gained variants in two disease genes, 
ROR2 and GLI3. The validation of causal regulatory variants is a central goal of functional 
genomics research. Here we demonstrate a reliable medium-throughput technique to detect 
regulatory effects of variants, which can be utilized as a valuable tool for variant validation. 
Understanding how genetic variation affects expression of genes across the genome in 
trans can give us a deeper understanding of how variation affects broad transcriptional networks 
in the cell. In chapter 3, we interrogate a particularly interesting immune-response eQTL, which 
is a cis-eQTL for IRF1 early after LPS stimulation and a trans-eQTL for many genes several hours 
after stimulation. To experimentally validate this association, we employed CRISPR/Cas9 genome 
editing and isolation of monoclonal cell lines followed by LPS stimulation and RNA-sequencing. 
Here we demonstrate the power of experimental investigation of master-regulatory variants, which 
contribute to inter-individual differences in cellular response to immune stimulus at a pathway 
level, potentially indicating mechanisms of disease-associated variants. 
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Chapter 2: A polyclonal allelic expression assay for detecting regulatory effects of 
transcript variants  
 
The experiments described in this chapter were conceived and designed by Margot Brandt with 
guidance from Tuuli Lappalainen. All experiments and analyses described in this chapter were 
performed by Margot Brandt with the following exceptions: 1) Alper Gokden and Marcello Ziosi 
performed a replicate of the polyclonal assay on the stop-gained, eQTL and control edited variants. 
The results presented in this chapter will be published as a paper with Margot Brandt as the first 
author (Brandt et al, in submission. https://www.biorxiv.org/content/10.1101/794081v1). 
Introduction 
 A method for scalable functional validation of regulatory variants associated with gene 
expression in human populations remains largely unaccomplished. Methods such as massively 
parallel reporter assays (MPRAs), which couple regulatory sequences with an expression reporter, 
are high-throughput and can be effective for finding active regulatory variants outside of the gene 
body, such as in enhancers. However, the results of the assays show low concordance with the 
direction of the population associations of the variants (Tewhey et al., 2016; van Arensbergen et 
al., 2019), perhaps due to taking the variant out of its genomic context. In addition, MPRAs are 
unsuited to validating variants found within the transcript: variants in exons, 5’ UTRs or 3’ UTRs. 
These variants are not compatible with MPRAs because they can act through post-transcriptional 
regulatory mechanisms affecting the stability of the transcript, as opposed to rate of transcription. 
A regulatory transcript variant can act by affecting splicing, inducing nonsense mediated decay 
(NMD) or impacting a miRNA binding site, for example. Posttranscriptional mechanisms have 
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been shown to be important for regulatory variants, with eQTLs being strongly enriched for 
transcript annotations (Aguet et al., 2019; Lappalainen et al., 2013). In order to validate these 
transcript variants, it is essential to introduce the variant into the native genomic context so that it 
can be incorporated into the transcript when the gene is transcribed by the cell. 
The advent of CRISPR/Cas9 genome editing technology (Cong et al., 2013; Jinek et al., 
2012; Shalem et al., 2014) has provided an avenue with which to introduce specific variants into 
the genome of cells in order to validate their effects on expression. However, editing one variant 
at a time, isolating hundreds of single cell clones, genotyping and expanding clones and measuring 
transcript abundance in both edited and wild type clones is a hugely time-consuming, expensive 
process. In addition to the resource cost of completing such an experiment, undetected large on-
target mutations (Kosicki et al., 2018), off-target mutations and other clone-specific genomic 
abnormalities can create noise which requires many replicates of each desired genotype in order 
to detect the effects of variants. To avoid undesirable clone-specific effects, we employed a method 
to validate the effects of regulatory variants in a polyclonal population of edited and wild type 
cells. 
We first set out to validate eQTL variants from GTEx fibroblasts using CRISPR in a human 
embryonic kidney cell line (293T). In addition to the variants being significantly associated with 
expression of genes, the eQTLs were also fine-mapped using CAVIAR (Hormozdiari et al., 2014). 
The CAVIAR posterior probability of association (PPA) assigned to each eQTL-associated variant 
gives the probability that the variant is causal, which helps distinguish causal eQTL variants from 
those variants in high linkage disequilibrium (LD) with the causal variant. By selecting variants 
for editing that have strong associations with the eQTLs as well as a high PPAs from fine-mapping, 
the chances of the variant truly being causal are increased.   
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In addition to validating eQTL variants, this assay can also be used for validating the effects 
of stop-gained variants on transcript stability. Stop-gained variants located 50-55 bp or more 
before the last exon junction are thought to induce NMD, while variants located beyond this 
threshold are thought to escape NMD and therefore produce truncated protein (Nagy and Maquat, 
1998). In order to establish this application, we first used the assay to analyze rare variants from 
individuals in GTEx which introduce a premature stop codon in the transcript prior to the 55-bp 
threshold.  
Understanding the effect of stop-gained variants on the transcript could have clinical utility 
as well. If a patient has a variant of unknown significance that introduces a stop codon prematurely 
into the transcript, it could be beneficial to validate the variant experimentally to be sure of its 
mechanism of action. This could be especially useful in cases where the disease mode of 
inheritance or severity of symptoms are dependent upon whether the variant induces NMD or 
results in the production of a truncated protein. To demonstrate the utility of the assay in this 
context, we selected two disease-associated genes GLI3 and ROR2. Stop-gained variants towards 
the beginning of GLI3 are associated with Greig cephalopolysyndactyly, while variants towards 
the end of the gene are associated with the clinically distinct Pallister-Hall syndrome (Johnston et 
al., 2005). It is hypothesized that Greig cephalopolysyndactyly is caused by haploinsufficiency of 
GLI3, while Pallister-Hall syndrome is caused by a dominant negative effect of truncated GLI3 
protein. Similarly, stop-gained variants towards the beginning of ROR2 are associated with the 
autosomal recessive Robinow syndrome, while variants towards the end of the transcript are 
associated with autosomal dominant Brachydactyly type B1 (Schwabe et al., 2000). Brachydactyly 
type B is thought to be caused by a dominant negative effect of truncated protein, since the 
recessive inheritance of Robinow Syndrome indicates haplosufficiency of the gene. The 
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association between variant position in the transcript and clinical manifestation of disease is 
hypothesized to be dependent upon whether the variant induces NMD or produces a truncated 
protein. For these two disease genes, we edited both disease-associated variants from ClinVar 
(Landrum et al., 2018) and artificial stop-gained variants falling on both sides of the NMD cutoff. 
Methods 
fgwas enrichment  
First, we sought to establish the relevance of testing eQTL effects driven by variants within 
transcripts by analyzing the extent of cis-eQTL enrichment in functional elements of the genome. 
We used GTEx v6 fibroblast eQTL data and a diverse  set of annotations: Gene annotations were 
obtained from GENCODE (Harrow et al., 2012), and regulatory annotations (CTCF-binding site, 
enhancer, open chromatin region, promoter, promoter-flanking region, and TF binding site) were 
obtained from the Ensembl regulatory build release 80 (Zerbino et al., 2015). Additional 
annotations include CADD variant consequence scores (Kircher et al., 2014), SPIDEX machine-
learning based prediction of splicing effects (Xiong et al., 2015), experimentally validated miRNA 
binding sites from Tarbase (Vergoulis et al., 2012), 3’ UTR regulatory elements (Oikonomou et 
al., 2014), and RNA-binding protein sites from CLIPdb (Yang et al., 2015). Significant fibroblast 
eQTLs were analyzed for enrichment in these functional annotations using fgwas (Pickrell, 2014), 
with each annotation tested separately. Annotations that are significantly enriched in eVariants 
over other non-significant variants include many annotations found within the transcript (figure 2-
1a). These include annotations involved in splicing, such as splice region variant, splice acceptor 
variant and SPIDEX predicted splicing.  Additionally, variants are enriched for annotations that 
affect transcript stability either through triggering nonsense mediated decay (stop-gained variant, 
frameshift variant) or by disrupting a binding site of a regulator within the transcript (miRNA 
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binding site, RNA binding protein site, 3’ UTR variant). Rare stop-gained variants in GTEx within 
the transcript affect transcript stability in an allele-specific manner (figure 2-1b). The bimodal 
pattern of allelic expression in stop-gained variants suggests that some variants affect the 
abundance of the transcript they are found in, as demonstrated by a high reference ratio (calculated 
as ref reads/ total reads), while some maintain a roughly 0.5 reference ratio. These findings 
emphasize the importance of regulatory variants within the transcript and the need for a method to 
validate them.  
 
Assay design 
In order to validate transcript regulatory variants’ allelic effects on transcript abundance, 
we utilized CRISPR/Cas9 genome editing with a gRNA specific to the locus of the variant of 
interest and a single-stranded DNA (ssDNA) template containing the alternative allele for 
homology-directed repair (HDR) (Figure 2-1c). For each variant of interest, we transfected the 
gRNA and ssDNA template into a well of inducible Cas9 293T cells. After editing, cells were 
harvested for gDNA and mRNA, followed by amplicon sequencing of the locus of interest in each. 
A regulatory effect of the variant is detected as a difference in the ratio of the alternative allele 
between gDNA and mRNA (figure 2-1d). This effect size is calculated as the log ratio of the 
alternative allele in cDNA over the ratio of the alternative allele in gDNA: log2(cDNA alt/ref / 
gDNA alt/ref), or the allelic fold change (aFC).  
 
Variant selection 
In this study, we edited five types of variants: GTEx stop-gained, GTEx eQTL, disease 
gene stop-gained, non-eQTL synonymous control, and synthetic control variants.  
   
 26 
Stop-gained variants from the general population were obtained from the GTEx v6 data 
release. Starting with all stop-gained variants that were singletons in GTEx v6, we used allele-
specific expression (ASE) data from the fibroblast sample of the individual carrying the variant to 
select those that are likely triggering NMD. The selected variants have RNA-seq coverage of >=20 
reads, a reference ratio Ref/(Ref+Alt) > 0.7, and are located in a gene with > 5 RPKM in a 
published HEK293 RNA-seq dataset (Sultan et al., 2014). Additionally, we required ASE data in 
at least 5 tissues and a first quartile of ASE across tissues of > 0.7 to select variants where NMD 
does not appear to be highly tissue-specific. Finally, we selected variants > 30 bp from the end of 
an exon for primer design. Nine variants were used for editing. 
eQTL variants were obtained from the GTEx v8 data release. Significant eQTL variants in 
fibroblasts were filtered for being within at least one protein-coding transcript, having a CAVIAR 
fine-mapping posterior probability of association > 0.8, an eGene with > 1 RPKM in HEK293 
cells, and an effect size in the top quartile of effect sizes of all associations (aFC > 0.30). The top 
33 highest effect size variants with successful gRNA and primer design were chosen for editing. 
Ten stop-gained variants for each of the disease genes GLI3 and ROR2 were created by 
changing a codon in the transcript to a stop codon.  The stop codons were spaced 20 bp apart in 
both directions from the NMD cutoff point (55 bp upstream of last the exon-exon junction).  The 
6 disease variants tested were obtained from ClinVar (Landrum et al., 2018), choosing disease-
associated variants in the two genes on either side of the NMD threshold. 
We selected 30 non-eQTL negative control variants from common synonymous variants 
in GTEx v8 data with an eQTL association p > 0.1 with the gene in which they reside. The 
templates for the 35 synthetic control variants were designed by introducing a nucleotide other 
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than the reference or alternative allele at the stop-gained variant locus, which does not create a 
premature stop codon. 
All variants edited with the assay can be found in Table 2-2. 
 
Cell culture 
Genome editing was carried out in a doxycycline-inducible Cas9 293T cell line, transduced 
with pCW-Cas9 plasmid (Addgene plasmid #50661 (Wang et al., 2014)), courtesy of the Sagi 
Shapira lab.  293T cells were cultured in OptiMEM (Gibco) supplemented with 5% HyClone 
Cosmic Calf Serum (Fisher), 1% Glutamax (Gibco), 1% NaPyr (Corning), and 1% 
penicillin/streptomycin (Corning). The cells were passaged and maintained following standard 
techniques in 5% CO2 and 95% air. 
 
Genome editing 
The protocol for the polyclonal editing assay can be found at 
dx.doi.org/10.17504/protocols.io.7c6hize. gRNAs were designed with E-CRISP version 5.3 
(Heigwer et al., 2014) using medium settings, with an NGG PAM, a 5’ G, excluding designs with 
more than 5 off-targets, and classifying off-targets as having up to 3 mismatches in 5’ region of 
the gRNA. gRNAs were ordered as gBlocks gene fragments (IDT): a U6 promoter sequence 
followed by the specific gRNA and tracr sequence (Arbab et al., 2015). The gBlocks were 
amplified using Q5 high fidelity 2X master mix (NEB) and locus-independent gBlock 
amplification primers (Arbab et al., 2015). Homologous templates were designed by extracting the 
sequence 50 bp upstream and downstream of each variant and substituting the reference allele with 
the alternative allele. Stop-gained control templates have another nucleotide substituted in the 
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variant position which does not create a stop codon. Homologous templates were synthesized as 
ultramers by IDT. If possible, primers which amplify both cDNA and gDNA were designed using 
IDT primer quest, choosing those that cover the PCR target (region spanning the variant and DSB) 
with at least 15 bp between the PCR target and one primer and at least 60 bp to the other primer. 
Otherwise, cDNA- and gDNA-specific primers were designed using either the cDNA or gDNA 
sequence as the template. Nextera adapter sequences were appended to forward and reverse primer 
sequences as follows:  
GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG+ForwardPrimerSequence 
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG+ReversePrimerSequence 
Primers were ordered as standard oligos from IDT.   
Twenty-four hours before transfection for CRISPR editing, iCas9 293T cells were plated 
in 24-well plates and induced with 5 ug/mL of doxycycline, with a separate well for each targeted 
variant. Cells were transfected with 500 ng homologous template and 500 ng gRNA gblock using 
Lipofectamine MessengerMAX transfection reagent (Thermo Fisher Scientific). After 24 hours, 
transfection reagent was removed and replaced with new media. Cells were split after 4 days and 
6 days, and DNA and RNA were extracted from the polyclonal edited cultures at 9 days. 75% of 
the 24-well culture was harvested for RNA using IBI Isolate DNA/RNA Reagent (IBI Scientific) 
according to the manufacturer’s instructions. Purified RNA was quantified by Nanodrop (Thermo 
Fisher). cDNA was synthesized with ~200 ng of purified RNA using 1/4 reactions of SuperScript 
IV VILO Master Mix with EZ DNase (Invitrogen).  Another 10% of the cell culture was used for 
DNA extraction using 15 uL of QuickExtract (Lucigen).  For the timecourse optimization 
experiment, mRNA and gDNA was extracted as above at days 4, 6 and 9.  
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Library preparation 
Amplicon libraries from cDNA and gDNA were created using either the same nextera 
primers (if possible) or separate nextera primers for cDNA and gDNA. 1 uL of cDNA or gDNA 
was amplified using Q5 High Fidelity 2X Master Mix (NEB). An indexing PCR was performed 
next using Nextera XT index kit primers (Illumina) and NEBNext High-Fidelity 2X PCR Master 
Mix (NEB) resulting in dual barcoded amplicons with illumina adapters. cDNA and gDNA 
libraries were mixed in equal volume and sequenced on the MiSeq using 150 bp paired-end reads. 
We obtained a median coverage of 85,000 reads per sample. 
 
Sequencing analysis 
Fastqs generated from Illumina software were trimmed for adapter sequences and quality 
using trimmomatic.  Reads were aligned to the gDNA or cDNA sequence specific for each 
amplicon and categorized as HDR, no edit, or NHEJ using EdiTyper (Yahi et al. in prep). Variants 
were eliminated if HDR in gDNA was greater than 30% (suggesting the cell line is in fact 
heterozygous for the variant). Samples were filtered out if they had fewer than 1000 reads covering 
the locus of interest. Additionally, samples were filtered out if they had an outlier NHEJ rate of 
greater than 80%, indicative of an alignment error. The effect size for each variant was calculated 
as the log2((Alt/Ref in cDNA) / (Alt/Ref in gDNA)), or allelic fold change (aFC).  An effect size 
of zero means the variant has no effect on transcript abundance.   
 
Statistical analysis 
Significance between the control variant distribution and the other experimental variant 
types was determined using a two-sided Wilcoxon rank sum test. An F test was utilized to detect 
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a difference in variance of aFC between non-eQTL control and synthetic control variants, and 
eQTL and control variants. For each individual regulatory variant, a p-value was calculated from 
the z-score of the variant’s effect size based on the mean and standard deviation of the control 
distribution. The p-values were then bonferroni corrected and variants with a corrected p-value of 
less than 0.05 were considered significant. 
 
eQTL effect size in GTEx 
 For the GTEx effect sizes for the eQTLs, we used the allelic fold change (aFC) estimates 
from the GTEx v8 data release (Aguet et al., 2019; GTEx Consortium et al., 2017; Mohammadi et 
al., 2017). For eQTL effect size in each GTEx tissue, we used the aFC estimates calculated from 
eQTL data. For stop-gained variants, we calculated aFC as the log2 ratio of the alternative and 
reference allele counts in the RNA-seq data in GTEx. To analyze the variation of eQTL variants’ 
effects across GTEx individuals, we calculated the aFC for each eQTL variant across heterozygous 
individuals in GTEx using the alternative and reference allele counts in the gene body 
(Mohammadi et al., 2017). Samples were filtered for those with greater than 50 reads covering 
heterozygous sites in the gene. 
 
eQTL variant characteristics analysis 
 LocusZoom plots were created for the eQTL variants using the p-values obtained from the 
GTEx v8 eQTL dataset and R2 linkage disequilibrium estimates from the same dataset. Predictions 
of the molecular effects of the eQTL variants for Table 2-1 were obtained using the Ensembl 
Variant Effect Predictor tool (McLaren et al., 2016).  
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Figure 2-1.  Variants found in the transcript are important for regulation of transcript abundance. 
(a) fgwas enrichment of functional annotations in GTEx fibroblast eVariants. Significant annotations are 
colored in purple. (b) Distribution of reference allelic ratio (reference reads/ total reads) in rare stop-gained 
variants found in individuals in GTEx. (c) For each potential regulatory variant of interest, we designed a 
gRNA and ssDNA template specific to the variant locus. (d) Polyclonal allelic expression assay to validate 
regulatory variants found in transcript. Inducible Cas9 293T cells undergo homologous recombination after 
transfection with the gRNA and ssDNA template in order to introduce the alternative allele to the cells. 
Editing is followed by targeted sequencing of gDNA and mRNA to detect the ratio of ALT/REF alleles in 
the polyclonal population of cells. 
 
Results 
Polyclonal allelic expression assay is a replicable method to validate regulatory variants 
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First, we assessed the right timepoint to harvest mRNA after transfection with CRISPR 
constructs. Since mRNA is likely to remain in the cell for hours to days after editing has occurred, 
we expect to see a depletion in edited mRNA molecules early after transfection. To find the optimal 
timepoint, we edited 17 control variants in 17 different genes which are not expected to have an 
effect on expression and harvested at three timepoints post-transfection: 4 days, 6 days and 9 days. 
At four days, we do see a depletion in the edited allele in the mRNA (figure 2-2a). However, this 
effect is lessened after 6 days and gone by 9 days. Therefore, we used the 9-day timepoint for the 
assay in order to analyze only the mRNA which has been transcribed post-editing.  
In order to determine the optimal set of negative control variants, we compared the 
distribution of effect sizes of the synthetic control variants (new variants created in the same genes 
as the stop-gained variants) and non-eQTL variants (common synonymous variants where eQTL 
effects were tested in GTEx and not observed). The synthetic control variants have several outlier 
variants with large effect sizes that are consistent in replicates (figure 2-2b). This suggests that a 
subset of synthetic variants affect transcript levels and are thus not ideal negative controls. The 
non-eQTL control variants, however, have effect sizes consistently close to zero (median aFC = -
0.009), demonstrating the utility of population data in selecting nonfunctional negative control 
variants.  The variance of the synthetic controls was significantly greater than the variance of the 
non-eQTL controls (1.02 versus 0.038; F test  p = 3.7x10-8). The non-eQTL variants were thus 
utilized as the control distribution for comparison with the stop-gained and eQTL variants tested 
with the assay. 
Next, we analyzed how technical variation in editing efficiency or PCR amplification may 
affect the robustness of the assay. We compared the HDR rate with standard deviation of effect 
size between editing replicates of 62 variants (2 replicates for 23 and 3 replicates for 32 variants). 
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We found that low HDR appears to be associated with a higher standard deviation in the calculated 
effect size from the assay (figure 2-2c). Therefore, moving forward, we discarded any variant with 
an HDR rate of less than 0.4% as determined by amplicon sequencing of the gDNA. The effect 
size is well correlated between two replicates of the same variants (Spearman’s rho = 0.53, p = 
2.8x10-3, figure 2-2d). The HDR rate is variable between loci, but very well correlated between 
replicates (Spearman’s rho = 0.95, p = 7x10-16, figure 2-2e), suggesting that the results of the assay 
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Figure 2-2. The polyclonal allelic expression assay is a replicable measure of variants’ allelic effects 
on transcript abundance. (a) Distribution of effect size for control variants over a timecourse post-
transfection. (b) Distribution of effect size for different control variant types: Synthetic and GTEx 
synonymous non-eQTL. (c) Homologous recombination rate versus standard deviation of effect size for 
variants replicated 2-3 times with assay. Vertical line shows 0.4% HDR cutoff which was used to filter 
variants for subsequent analysis. (d) Scatter plot showing reproducibility of effect size (allelic fold change) 
detected by polyclonal allelic expression assay in two editing replicates of the same variants. (e) Scatter 
plot showing correlation of HDR between the two replicates.  
 
Edited stop-gained variants cause an allele-specific decrease in mRNA 
The first variants selected for evaluation using the polyclonal allelic expression assay were 
rare stop-gained variants from GTEx. The alternative allele of these variants introduces a stop 
codon into the gene and shows evidence of allelic expression in GTEx heterozygous individuals 
as demonstrated by a decreased presence of the alternative allele in the mRNA (reference 
reads/total reads > 0.7 in GTEx).  
The stop variants were expected to have a negative effect size by triggering NMD in the 
cell, which is what we observed (figure 2-3a), with the distribution of the effect size of the stop 
variants being significantly lower than the non-eQTL control variants (Wilcoxon signed rank p = 
3.26x10-5). The fact that the effect size of the edited stop-gained variants is in the expected 
direction consistent with NMD, an effect which is absent in the control variants, lends support for 
the assay capturing NMD effects of variants. As compared to the control variants, five of the stop-
gained variants deviate significantly from the control distribution (Bonferroni-corrected z-test 
p<0.05).  
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Figure 2-3. Stop-gained and eQTL variants from GTEx show allele-specific regulatory effects on 
expression. (a) Effect size of non-eQTL control, eQTL and stop-gained variants after editing with the 
polyclonal assay. Triangular points mark variants whose effect sizes significantly deviate from the control 
distribution. (b) Correlation between effect size observed in GTEx and effect size resulting from polyclonal 
assay for non-eQTL control, eQTL and stop-gained variants. Triangular points mark variants whose effect 
sizes significantly deviate from the control distribution. 
 
eQTL variants have a larger regulatory effect than control variants 
Next, we extended the assay to assess putatively causal eQTL variants within transcripts 
using GTEx fibroblast eQTLs. We chose fibroblasts because GTEx fibroblast transcriptome 
expression is highly correlated with that of HEK293 cells (rho = 0.68, p < 2.2x10-16). The 33 eQTL 
variants chosen for editing are located within the transcript of the eGene with which they are 
associated and have a high posterior probability of causality based on CAVIAR fine mapping. 
After editing and QC filtering, 13 eQTL variants remained. The variance of the effect size of the 
eQTL variants was significantly higher than that of the control variants (0.49 versus 0.038; F-test 
p = 1.65x10-5; figure 2-3a), which suggests that the edited eQTL variants as a whole have a greater 
regulatory effect than the edited control variants. Ten of the 13 variants have an effect in the same 
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direction as the GTEx eQTL effect. Five of the eQTL variants are individually significantly 
different from the control distribution (figure 2-3a), and all five of these variants have an effect in 
the same direction as in GTEx. Additionally, there is a significant correlation between the effect 
size of the edited stop-gained, non-eQTL control and eQTL variants and their effects in GTEx 
(Spearman’s rho = 0.62; p = 5x10-5; figure 2-3b), again indicating that the assay captures regulatory 
effects seen in the population.  
eQTL variant effects vary across tissues and individuals 
The lack of effect observed for some of the eQTL variants could be due to our cell line not 
perfectly recapitulating the genetic regulatory effects in GTEx fibroblast samples. To investigate 
this, we looked at variation in effect size between GTEx tissues for each of the eQTL variants 
(figure 2-4a). We also looked at inter-individual variation within fibroblast samples in GTEx, 
which may reflect more subtle cell type-specific genetic effects as well as the effects of other 
regulatory variants in the GTEx individuals. We measured the effect size in eQTL heterozygotes 
in GTEx based on allelic imbalance within the gene body (figure 2-4b), with eleven of the eQTL 
variants having sufficient data for this analysis. For all five significant variants, there is agreement 
in direction between the polyclonal aFC, median heterozygous aFC across individuals and median 
eQTL aFC across tissues. For several of the other variants, figures 2-4a and b demonstrate a large 
range of effects both across tissues and across individuals. The observed effect of a variant in the 
cell line of our assay, like an individual or tissue, is likely to fall somewhere in a spectrum of 
possible effects. We note that for some of the variants the effect detected in our assay is consistent 
with the eQTL effect but the assay does not currently have sufficient sensitivity to assign this as a 
significant effect.  
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Another even more likely possible explanation for the lack of effect in some eQTL variants 
is that the top variant was incorrectly identified by fine mapping and there is another true causal 
variant. To test this hypothesis, we looked at the p-value distributions for the edited eQTL variants 
to see if there are other highly significant variants that could be driving the eQTL association. 
There does not appear to be a difference in the p-value distributions between the significant (figure 
2-4c and d) and non-significant eQTL variants (figure 2-4e and f). In both cases, there are examples 
of distributions which appear to have other likely causal variants (figure 2-4c and e) and those that 
seem to have a clear top variant (figure 2-4d and f).  
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Figure 2-4. Characteristics of the eQTL edited variants. (a) eQTL effect size (aFC) in GTEx tissues for 
the 13 edited eQTL variants shown as boxplots, with lines indicating the median effect size in GTEx 
fibroblasts (red) and in the assay (purple). Asterisks mark variants which were significant in the assay. (b) 
aFC in GTEx fibroblasts, measured in eQTL heterozygous individuals for 11 of the edited eQTL variants. 
(c-d) Locus zoom plots showing p-values and LD for variants tested for eQTL association for two 
representative significant eQTL variants from the polyclonal assay. (e-f) Locus zoom plots showing p-
values and LD for variants tested for eQTL association for two representative non-significant eQTL variants 
from the polyclonal assay. 
 
To further test the hypothesis that some of the non-significant eQTL variants are not causal, 
we used the Ensembl variant effect predictor (VEP) (McLaren et al., 2016) to determine the likely 
molecular consequences of the eQTL variants on their respective genes (Table 2-1). All five of the 
significant eQTL variants fall into the promoter region of the gene, while five out of eight non-
significant variants fall into promoters. Interestingly, three out of five significant eQTLs fall into 
high-info positions within transcription factor (TF) motifs, suggesting they have an impact on 
binding of the TF, while none of the nonsignificant variants fall into high-info positions (fisher 
test, p = 0.035). This result suggests that the assay can distinguish true causal variants disrupting 
genetic regulatory elements from eQTL variants that are not causal.  
To compare our assay to another method of eQTL validation, we compared our results to 
the results from a large MPRA study (van Arensbergen et al., 2019). Of the three of our significant 
eQTL variants that are found in their data, one variant (chr4_139665971_A_T_b38) has a 
nominally significant negative effect in both cell types used in that study, consistent with our 
results. Three of our non-significant eQTL variants (chr17_81294933_T_C_b38, 
chr20_25057848_G_T_b38 and chr2_170816965_G_A_b38) are nominally significant in that 
study and two are not. The overlap of significant variants is not expected to be especially high 
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since the assays likely have different sensitivities and in the MPRA the variants are tested out of 
the genomic context.  
 
 
Table 2-1. Variant effect predictions for the eQTL edited variants. Predicted effects of the edited eQTL 
variants based on Ensembl Variant Effect Predictions. 
 
The polyclonal assay distinguishes disease variants which cause NMD from those that do not 
In order to apply our assay to the detection of nonsense-mediated decay triggered by 
disease-associated variants, we introduced stop-gained variants into two disease-associated genes: 
ROR2 and GLI3. Seven of the edited stop-gained variants fall before the 55 bp threshold and were 
therefore expected to trigger NMD. Of these variants, all seven resulted in negative effect sizes 
and the distribution of these variants was significantly different from that of both the four variants 
which were not expected to trigger NMD (Wilcoxon p = 6.1x10-3) and the non-eQTL control 
variants (Wilcoxon p = 5.8x10-4, figure 2-5a). When tested individually, six of the seven expected 










s chr1_20508117_C_A_b38 X X X X
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chr11_44066439_G_T_b38 X X X
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NMD variants are significantly different from the control distribution, indicating that we can 
sensitively detect NMD and NMD- escape across the 55-bp boundary in these two genes.  
In addition to the newly created stop-gained variants, we also included disease-causing 
stop-gained variants from ClinVar. The Arg442Ter mutation in ROR2 results in a stop-codon right 
before the predicted NMD cutoff and is associated with the recessively inherited Robinow 
syndrome. We observe a significant negative effect of this variant (aFC = -1.39, Bonferroni 
corrected z-test p = 2.2x10-11), which is consistent with NMD and the clinical manifestation of 
disease (figure 2-5b). In contrast, the variant Trp749Ter is associated with dominant Type B 
brachydactyly and falls after the NMD cutoff in the transcript.  Our assay shows that Trp749Ter 
does not affect the expression level of ROR2 and therefore does not appear to be triggering NMD 
(aFC = -0.17, corrected p = 1). The one disease variant tested in GLI3, Arg792Ter, falling 
immediately before the predicted border of NMD escape, shows evidence of triggering NMD with 
a negative effect size in the assay (aFC = -1.02, corrected p = 3.6x10-6).  This result is consistent 
with the clinical features of this variant, since it is associated with Grieg cephalopolysyndactyly 
syndrome which is thought to be caused by haploinsufficiency in the gene GLI3. The results of 
editing stop-gained variants in these disease genes indicate that there is a sharp cutoff of NMD / 
NMD-escape at the previously described 50-55 bp threshold and pinpoint the immediate molecular 
mechanism of NMD / NMD-escape for these disease variants. Additionally, the results 
demonstrate the potential for utilizing this assay to assess whether a variant of clinical interest 
triggers NMD when it falls close to the threshold of NMD escape.  
   
 42 
 
Figure 2-5. Stop-gained variants in disease-associated genes show expected regulatory effect based 
on position in transcript. (a) Effect size in control variants, stop-gained variants after NMD threshold, and 
stop-gained variants before NMD threshold. Triangular points mark variants whose effect size significantly 
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GLI3, showing the effect size (y-axis) and position in the transcript (x-axis) for each successfully edited 
variant. Disease- associated variants from ClinVar are labeled in red. 
 
Discussion 
In this study, we described a method utilizing CRISPR/Cas9 genome editing and targeted 
sequencing to validate regulatory variants without the need for isolating monoclonal cell lines. We 
demonstrated our ability to reliably detect the effects of stop-gained variants in the general 
population and in disease cases with the assay. The ability to experimentally assess the effect of 
potentially disease-causing stop-gained variants could lead not only to better understanding of the 
rules of NMD / NMD-escape, but also more accurate diagnosis and prognosis. The American 
College of Medical Genomics recommends caution in interpreting pathogenicity of stop-gained or 
frameshift variants of unknown significance, especially in cases where the variant is in an exon 
which might be alternatively spliced, or close to the 3’ end of the transcript (Richards et al., 2015). 
Even though RNA analysis from patients is increasingly used to support variant interpretation 
(Ben-Shachar et al., 2009; Cummings et al., 2017; Kremer et al., 2017), establishing causality has 
been difficult since lower expression of a mutant haplotype or gene could be driven by other 
genetic or environmental factors. Our approach provides evidence that introduction of the specific 
variant in question underlies transcript level changes, thus reducing ambiguity. Furthermore, for 
genes where NMD / NMD-escape is clinically relevant, saturation editing at the 50-55-bp border 
could build a high-resolution reference for variant interpretation.  
This polyclonal assay has the ideal throughput for identifying causal variants from a list of 
a few to several dozen candidate variants discovered from a rare genetic study. It would be feasible 
to perform the polyclonal assay on a number of potential regulatory variants, sequencing mRNA 
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and gDNA from the polyclonal culture, and then sort monoclonal cell lines from the same 
polyclonal culture for only the variants which demonstrate allele-specific regulatory activity. 
When we applied the polyclonal assay to eQTL variants, we detected increased effects on 
expression levels as compared to controls, often in the same direction as the GTEx eQTL effect. 
Five of 13 variants had significant effects, all consistent with the GTEx eQTL data. This clearly 
demonstrates the ability of our assay to capture common regulatory variant effects. Some of the 
non-significant eQTL variants appear to have edited effect sizes consistent with GTEx, but we 
lack the sensitivity to detect these small effects with confidence. In addition, some of the 
inconsistencies between the assay results and eQTL data are likely to originate from the eQTL 
data. Since we do not expect fine mapping to always succeed in identifying the true causal variants 
at these loci, the undetected effects could represent these situations. Furthermore, with multiple 
eQTLs for the same gene being common (GTEx Consortium et al., 2017), it is possible that eQTL 
effect sizes observed in populations reflect multiple regulatory variants in partial LD. Therefore, 
editing a single variant may not yield the same results as the full haplotype. When we looked at 
the aFC in heterozygous individuals for these variants in GTEx, we found a broad range of effect 
sizes, suggesting the presence of effects from multiple variants and potential modifiers that may 
not be captured by editing a single variant. Finally, assessing genetic regulatory effects even in 
closely matched cell lines does not necessarily capture effects measured in tissue samples. While 
this is likely to contribute to some of the differences, cis-eQTLs, especially in the transcribed 
region, are often highly robust across different tissues (GTEx Consortium et al., 2017), and are 
expected to replicate in cell lines as well. We highlight that our approach maintains the genomic 
context of variants and native gene regulation. Thus, it does not suffer from the limitations of 
massively parallel approaches where discrepancies between eQTL and experimental data may be 
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due to measuring genetic regulatory effects in artificial constructs (Tewhey et al., 2016; van 
Arensbergen et al., 2019). Altogether, more experimentation and further comparison of population 
and experimental results are required to fully understand differences between experimental and 
population data. 
Finally, we note that our assay is somewhat limited by HDR efficiency, which varies 
greatly between loci. Capturing the specific effect of the edited variant requires discarding any 
reads in the gDNA or cDNA which contain indels created through non-homologous end joining 
(NHEJ). Since NHEJ often dominates HDR in efficiency, this can result in low numbers of HDR 
reads. Research in improving the HDR rates in editing is ongoing (Aird et al., 2018; Chu et al., 
2015; Maruyama et al., 2015), and likely HDR efficiency will be greatly improved in the future. 
Additionally, future improvements on base editor technology, which avoids the introduction of 
double stranded breaks and therefore minimizes the risk of indels (Gaudelli et al., 2017; Komor et 
al., 2016), could also benefit this system and increase sensitivity of the assay.   
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 Table 2-2. All variants edited with the polyclonal allelic expression assay in chapter 2. 
Variant 






allele gRNA seq 
stop 
gained stop_1 1 10463557 G A GTGTGTGCTGCAGCCGCTGGA 
stop 
gained stop_2 1 113981146 C T GGGTGAAGTCACGCAGCCTT 
stop 
gained stop_3 1 946463 G T GCAGCTGCTTGGGAAGGTTC 
stop 
gained stop_5 19 18784264 G A GTGGAAGGACCCGCGAAACG 
stop 
gained stop_6 2 200651022 C T GGCATTGATCTCTTGTTTGTA 
stop 
gained stop_7 20 44948809 C A GGCAATGAGCTTGTAAAGAA 
stop 
gained stop_8 22 36512560 G A GAAGCTGGACTCTCAGCGAG 
stop 
gained stop_9 3 49122992 G A GCCCATCCTCATCTCGACAGC 
stop 
gained stop_10 5 154821355 C T GAGGGCCAAGGAAAACCACA 
eQTL chr1_20508117_C_A_b38 1 20508117 C A GTTTCCGGTCAGGTTAGGCC 
eQTL chr10_16817401_G_C_b38 10 16817401 G C GCGTGTTCGCTGTTCAGTGC 
eQTL chr11_44066439_G_T_b38 11 44066439 G T GGCTCCAGGTTTCCAGGCAG 
eQTL chr15_64156166_C_T_b38 15 64156166 C T GTGGAAGCAGGAGGGCATGG 
eQTL chr16_70157320_G_A_b38 16 70157320 G A GCAGCCTATTAGTTCTGGTG 
eQTL chr19_32972322_C_T_b38 19 32972322 C T GGTTCCTGCCGGCTGTATTC 
eQTL chr19_32972339_A_G_b38 19 32972339 A G GCTGTATTCGGGCCTTGGAC 
eQTL chr19_984554_C_G_b38 19 984554 C G GCAAGAATTACATCAGCGCC 
eQTL chr2_170816965_G_A_b38 2 170816965 G A GCCCAGCGATCCGCTCGGCT 
eQTL chr2_9843557_G_T_b38 2 9843557 G T GCCTCCTTACCGCCTCCTCG 
eQTL chr20_1325648_T_C_b38 20 1325648 T C GCTTTAAACTCCCCTGGCCT 
eQTL chr20_3213332_G_A_b38 20 3213332 G A GATAAGTGCCGGAGTACCAG 
eQTL chr22_36507049_C_T_b38 22 36507049 C T GCGCGGCCTCATTAGACCAC 
eQTL chr4_41990735_G_C_b38 4 41990735 G C GCTCCGTCTGCGATGCAGGG 
eQTL chr8_144414270_T_C_b38 8 144414270 T C GGCAGTGGGTGCAGTCACTG 
eQTL chr5_56909530_A_G_b38 5 56909530 A G GGTGCCAGGAACACTGAGAG 
eQTL chr3_33218930_C_T_b38 3 33218930 C T GCGCTCGGCTCACGAATCGC 
eQTL chr7_4768773_G_A_b38 7 4768773 G A GAGCGGGGAGAGTGGTGAGG 
eQTL chr19_9324196_C_T_b38 19 9324196 C T GCGTGGGCGCATGCGCATAA 
eQTL chr8_544804_C_G_b38 8 544804 C G GCCGCAGGCAGAGCGTCCGG 
eQTL chr16_89972488_G_C_b38 16 89972488 G C GATCAAACCCTCGAACGGTC 
eQTL chr4_139665971_A_T_b38 4 139665971 A T GAACTATTTGTAGAGCGCAC 
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eQTL chr1_147647471_G_A_b38 1 147647471 G A GAGTTTGAGAGCAGAGTGCG 
eQTL chr1_27335461_C_T_b38 1 27335461 C T GGCCACCGAGCAGCCATCAC 
eQTL chr1_197902889_G_T_b38 1 197902889 G T GAGCGAAGAGTTAACCGCGG 
eQTL chr20_25057848_G_T_b38 20 25057848 G T GTCCCAGACGGTGTGGTAGG 
eQTL chr7_90211993_G_A_b38 7 90211993 G A GGGCGAGCCTTGCAGCTCCC 
eQTL chr3_100709512_A_G_b38 3 100709512 A G GAGAACTTGGGCTCTGTACG 
eQTL chr9_133361131_C_T_b38 9 133361131 C T GGCATGTGCTTTTATTAACC 
eQTL chr12_51199833_T_G_b38 12 51199833 T G GCTGAAGGTGGCAATGGCAG 
eQTL chr16_88706338_C_T_b38 16 88706338 C T GCGCGGGCCTGGCCCCGGGA 
eQTL chr19_57840921_G_A_b38 19 57840921 G A GACAGGTGTGTCTCCCAAGA 
eQTL chr17_81294933_T_C_b38 17 81294933 T C GGTCATAGTGAGAGGTCTAG 
ROR2 
stop ROR2_exp_1 9 
91725057-
91725059 CAG CTA GTCTGCGGTGAGGTTCATGG 
ROR2 
stop ROR2_exp_2 9 
91725078-




stop ROR2_exp_3 9 
91725099-




stop ROR2_exp_4 9 
91726553-
91726555 GTT CTA GGCATGGAGACCTGTTTGTGC 
ROR2 
stop ROR2_exp_5 9 
91726574-
91726576 GTC CTA GCCATCAGCTGTCGCCGCTG 
ROR2 
stop ROR2_exp_6 9 
91726616-
91726618 GGA CTA GCCATCAGCTGTCGCCGCTG 
ROR2 
stop ROR2_exp_7 9 
91726637-
91726639 ATT CTA GCCATCAGCTGTCGCCGCTG 
ROR2 
stop ROR2_exp_8 9 
91726658-
91726660 GAA CTA GAAAAGGCAAGCGATGACCAG 
ROR2 
stop ROR2_exp_9 9 
91726679-
91726681 CAG CTA GAAAAGGCAAGCGATGACCAG 
ROR2 
stop ROR2_exp_10 9 
91726700-
91726702 GAC CTA GAAAAGGCAAGCGATGACCAG 
ROR2 
stop ROR2_exp_Arg442Ter 9 91726603 G A GCCATCAGCTGTCGCCGCTG 
ROR2 
stop ROR2_exp_Trp720Ter 9 91724334 C T GCGGGACAGTCATCGGGGCA 
ROR2 
stop ROR2_exp_Trp749Ter 9 91724248 C T GTAGTTGGAAAGGTTGCCCC 
GLI3 
stop GLI3_exp_1 7 
41966592-
41966594 GAG CTA GGGCCCATGACGCTTCTCCC 
GLI3 
stop GLI3_exp_2 7 
41966613-
41966615 CAA CTA GGGCCCATGACGCTTCTCCC 
GLI3 
stop GLI3_exp_3 7 
41966635-
41966637 CTG CTA GTCCAACAACACCTGCAGCT 
GLI3 
stop GLI3_exp_4 7 
41967609-
41967611 AGG CTA GAGAGACCGCAGGGGCTTTA 
GLI3 
stop GLI3_exp_5 7 
41967630-
41967632 AGG CTA GAGAGACCGCAGGGGCTTTA 
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GLI3 
stop GLI3_exp_6 7 
41967672-
41967674 TTG CTA GAAAGGCTAAAACAAGTGAA 
GLI3 
stop GLI3_exp_7 7 
41967693-
41967695 TAC CTA GAAACCCGGCAGGGACCAAA 
GLI3 
stop GLI3_exp_8 7 
41967714-
41967716 CCC CTA GAAACCCGGCAGGGACCAAA 
GLI3 
stop GLI3_exp_9 7 
41967735-
41967737 TTG CTA GGCTTGCAAAGCAAGGGCTG 
GLI3 
stop GLI3_exp_10 7 
41967756-
41967758 TGC CTA GGCTTGCAAAGCAAGGGCTG 
GLI3 
stop GLI3_exp_Ser856Ter 7 41966506 G T GTAGGCCGAGCTGATGGTGC 
GLI3 
stop GLI3_exp_Arg792Ter 7 41967653 G A GGTAGAATGGGGTTCAGTCG 
GLI3 
stop GLI3_exp_Gln717Ter 7 41967878 G A GTTGGAATAGTTGCTGATGG 
syntheti
c control stop_con_1 1 10463557 G T GTGTGTGCTGCAGCCGCTGGA 
syntheti
c control stop_con_2 1 113981146 C A GGGTGAAGTCACGCAGCCTT 
syntheti
c control stop_con_3 1 946463 G A GCAGCTGCTTGGGAAGGTTC 
syntheti
c control stop_con_5 19 18784264 G T GTGGAAGGACCCGCGAAACG 
syntheti
c control stop_con_6 2 200651022 C A GGCATTGATCTCTTGTTTGTA 
syntheti
c control stop_con_7 20 44948809 C T GGCAATGAGCTTGTAAAGAA 
syntheti
c control stop_con_8 22 36512560 G T GAAGCTGGACTCTCAGCGAG 
syntheti
c control stop_con_9 3 49122992 G T GCCCATCCTCATCTCGACAGC 
syntheti
c control stop_con_10 5 154821355 C G GAGGGCCAAGGAAAACCACA 
non-
eQTL 
control syn1 11 88294225 A C GGTCTCTTAGACCAGTGTGG 
non-
eQTL 
control syn2 14 104887068 G A GTGAGGGGGGCAGCACCCCG 
non-
eQTL 
control syn3 17 40822211 G A GGAGGCGGCTTTGGTGGAGG 
non-
eQTL 
control syn4 17 79086238 C T GAAATTCCATGCGACGATCC 
non-
eQTL 
control syn5 17 80010342 C T GGATGTCACCGAGGAGGGGC 
non-
eQTL 
control syn6 19 58294717 T C GGATGCGCTCATGCTGGACG 




control syn7 22 50523830 G A GGCAACCTGTTTGGTGGAGC 
non-
eQTL 
control syn8 7 143863472 T G GAGTGGCCTCCTCGCAGTGG 
non-
eQTL 
control syn9 1 27366484 G T GCCGGCTCCGCGCGCAGCCC 
non-
eQTL 
control syn10 1 3883678 A G GTCACAGTTGAGCTTGTGGG 
non-
eQTL 
control syn11 10 69180435 C T GTTTGGTATTTTGGAGCCAC 
non-
eQTL 
control syn12 11 126304143 C T GCGCGAATTGGACGTGGAGG 
non-
eQTL 
control syn13 14 76776147 C T GCGGGTCGTGTGACACGCTC 
non-
eQTL 
control syn14 16 69330127 G A GGTTCACGAACACGCGCAGG 
non-
eQTL 
control syn15 16 88715671 G A GCGGTAGAGGAAGATGAGCT 
non-
eQTL 
control syn16 16 88721329 C T GGAGGGGCCAGGGGTGCCTG 
non-
eQTL 
control syn17 17 15945284 G T GGACGCGCTGTACGTGGCGC 
non-
eQTL 
control syn18 17 15945323 C T GGTCATCGCCGCGCTTTCGG 
non-
eQTL 
control syn19 17 15999680 C G GGAGGATCCTGACCCCCCGC 
non-
eQTL 
control syn20 17 59213022 G A GCCTGTCGATCAACGAAGTT 
non-
eQTL 
control syn21 17 75909713 C T GGGGAGAGGCACGTGGCCAG 
non-
eQTL 
control syn22 18 23529181 G A GGTTTTTTTCTTTCAGGCGG 
non-
eQTL 
control syn23 19 3959446 G A GGCTGCGCTGCAGCTCGCGC 




control syn24 21 42903351 G A GTCTTTCTTGACAAAAATTT 
non-
eQTL 
control syn25 5 10239241 C T GTTCTTACTTACTGGGCTTG 
non-
eQTL 
control syn26 6 108074445 C A GCCCCAGCCCTCCACCCTGC 
non-
eQTL 
control syn27 6 139167023 C T GCCGCCGAAGGAACTGCACG 
non-
eQTL 
control syn28 7 156950085 C A GAACAGGGTCCCGGCCTGGG 
non-
eQTL 
control syn29 7 726792 G A GGCCGAGACGGCTGAGGCGG 
non-
eQTL 
control syn30 8 143650949 G A GCTGGGTGAAGTTTGACGTC 
syntheti
c control ROR2_con_1 9 
91725057-
91725059 CAG TAG GTCTGCGGTGAGGTTCATGG 
syntheti
c control ROR2_con_2 9 
91725078-




c control ROR2_con_3 9 
91725099-




c control ROR2_con_4 9 
91726553-
91726555 GTT ATT GGCATGGAGACCTGTTTGTGC 
syntheti
c control ROR2_con_5 9 
91726574-
91726576 GTC ATC GCCATCAGCTGTCGCCGCTG 
syntheti
c control ROR2_con_6 9 
91726616-
91726618 GGA TGA GCCATCAGCTGTCGCCGCTG 
syntheti
c control ROR2_con_7 9 
91726637-
91726639 ATT GTT GCCATCAGCTGTCGCCGCTG 
syntheti
c control ROR2_con_8 9 
91726658-
91726660 GAA AAA GAAAAGGCAAGCGATGACCAG 
syntheti
c control ROR2_con_9 9 
91726679-
91726681 CAG TAG GAAAAGGCAAGCGATGACCAG 
syntheti
c control ROR2_con_10 9 
91726700-
91726702 GAC TAC GAAAAGGCAAGCGATGACCAG 
syntheti
c control ROR2_con_Arg442Ter 9 91726603 G T GCCATCAGCTGTCGCCGCTG 
syntheti
c control ROR2_con_Trp720Ter 9 91724334 C G GCGGGACAGTCATCGGGGCA 
syntheti
c control ROR2_con_Trp749Ter 9 91724248 C G GTAGTTGGAAAGGTTGCCCC 
syntheti
c control GLI3_con_1 7 
41966592-
41966594 GAG AAG GGGCCCATGACGCTTCTCCC 
syntheti
c control GLI3_con_2 7 
41966613-
41966615 CAA TAA GGGCCCATGACGCTTCTCCC 
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syntheti
c control GLI3_con_3 7 
41966635-
41966637 CTG TTG GTCCAACAACACCTGCAGCT 
syntheti
c control GLI3_con_4 7 
41967609-
41967611 AGG GGG GAGAGACCGCAGGGGCTTTA 
syntheti
c control GLI3_con_5 7 
41967630-
41967632 AGG GGG GAGAGACCGCAGGGGCTTTA 
syntheti
c control GLI3_con_6 7 
41967672-
41967674 TTG CTG GAAAGGCTAAAACAAGTGAA 
syntheti
c control GLI3_con_7 7 
41967693-
41967695 TAC CAC GAAACCCGGCAGGGACCAAA 
syntheti
c control GLI3_con_8 7 
41967714-
41967716 CCC TCC GAAACCCGGCAGGGACCAAA 
syntheti
c control GLI3_con_9 7 
41967735-
41967737 TTG CTG GGCTTGCAAAGCAAGGGCTG 
syntheti
c control GLI3_con_10 7 
41967756-
41967758 TGC GGC GGCTTGCAAAGCAAGGGCTG 
syntheti
c control GLI3_con_Ser856Ter 7 41966506 G A GTAGGCCGAGCTGATGGTGC 
syntheti
c control GLI3_con_Arg792Ter 7 41967653 G T GGTAGAATGGGGTTCAGTCG 
syntheti
c control GLI3_con_Gln717Ter 7 41967878 G T GTTGGAATAGTTGCTGATGG 
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Chapter 3: A distant cis-eQTL for IRF1 is a trans-eQTL master regulatory variant in 
immune response 
 
All experiments described in this chapter were conceived and designed by Margot Brandt with 
guidance from Tuuli Lappalainen. All experiment and analyses described in this chapter were 
performed by Margot Brandt with the following exceptions: 1) Sarah Kim-Hellmuth performed 
the immune-respone cis- and trans-eQTL study in which the IRF1 signal was discovered. 2) Aaron 
Wollman transfected the hTLR4 cells and performed the T7E1 assay to confirm editing in 
polyclonal cell population 3) Alper Gokden performed the long-range PCR on the clonal cell lines. 
4) Marcello Ziosi performed the CRISPRi transfection and LPS stimulation of the hTLR4 cells, 5) 
Yocelyn Recinos tested the optimal time point for hTLR4 cell immune stimulus.  
Introduction 
 Understanding the link between noncoding variants and their effects on genes can help 
interpret variants associated with disease which fall in the noncoding genome. Doing so in a static 
environmental context is how classic eQTL studies are done. However, looking for associations in 
specific environmental contexts can further reveal how regulatory variants act in a cell under 
variable conditions. This is especially relevant for immune cells, such as monocytes, whose 
physiological function is dependent upon rapid transcriptional changes in response to stimulus. 
Immune-response eQTL (reQTL) studies are designed with this goal in mind: to identify regulatory 
variants whose effects are dependent upon the presence or absence of a stimulus. Such variants 
can contribute to genetic inter-individual variation in immune response – a widespread 
   
 53 
phenomenon that underlies many human infectious and autoimmune diseases  (Fairfax et al., 2014; 
Kim-Hellmuth et al., 2017; Lee et al., 2014). 
 The innate immune response to lipopolysaccharides (LPS), molecules found on the outer 
membrane of gram-negative bacteria, is transduced through toll-like receptor 4 (TLR4), which is 
found on the surface of many immune cells, including monocytes. TLR4 cooperates with MD2 
and CD14 to recognize LPS outside the cell. Once bound to LPS, TLR4 undergoes a 
conformational change which triggers a signaling cascade, activating NF-kB and increasing 
transcription of its targets, including proinflammatory cytokines and type I interferons (Lu et al., 
2008).  
 Immune-reQTL studies in monocytes have identified variants which affect the expression 
of genes involved in the innate immune response, which can explain quantitative differences in 
immune response between individuals (Chen et al., 2016; Fairfax et al., 2014; Kim et al., 2014). 
A cis-reQTL is where a variant is associated with expression of a proximal gene, whereas a trans-
reQTL is where a variant is associated with a distal gene. A previous immune-reQTL study (Kim-
Hellmuth et al., 2017) discovered 126 significant cis-reQTLs in human monocytes which were 
active under stimulation with LPS. One such cis-reQTL for IRF1 is not significant under baseline 
but is a significant eQTL under stimulation with LPS. In addition to being implicated in immune 
cell lineage development, IRF1 has been shown to be involved in activation of macrophages via 
the IFN-g receptor (Langlais et al., 2016). Another study showed that IRF1-deficient macrophages 
have reduced IL-12 cytokine induction after stimulation with LPS (Liu et al., 2003), implicating 
IRF1 in TLR4 signaling in response to LPS. Furthermore, IRF1-knockout mice have been shown 
to have increased survival after infection with LPS as compared to matched control mice (Pan et 
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al., 2013). However, the full extent of the involvement of IRF1 in TLR4 signaling has not yet been 
elucidated. 
Trans-eQTLs, associations between variants and genes which are mediated by a secondary 
factor, are more difficult to detect than cis-eQTLs. In addition to the multiple testing burden 
imposed by testing all variants against all genes, trans-eQTLs also tend to have smaller effect sizes 
(Aguet et al., 2019). However, there is evidence that trans-eQTLs are particularly important for 
understanding mechanisms of disease-associated variants, as GWAS associations for complex 
traits are strongly enriched for trans-eQTLs (Aguet et al., 2019). Furthermore, since they provide 
information on how genetic perturbations affect transcriptional networks, trans-eQTLs have the 
potential to elucidate cellular pathways affected by genetic variants. However, while trans-eQTL 
detection has somewhat improved recently with larger sample sizes (Võsa et al., 2018), there has 
still been very little validation of these associations.  
In this study, we first associated the cis-reQTL variants from Kim-Hellmuth et al. with all 
expressed genes in monocytes in order to detect trans associations. One trans-eQTL near IRF1 is 
of particular interest due to its association with IRF1 in cis early after LPS stimulation and delayed 
association with a large number of genes in trans. This result suggests the association is a 
condition-specific trans-eQTL with potentially broad effects on an individual’s response to LPS. 
Therefore, we chose to follow up on this trans-eQTL master regulatory variant using CRISPRi 
gene expression perturbation and CRISPR/Cas9 genome editing in an immune cell line to replicate 
the variant’s effects. 
Methods 
eQTL discovery 
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The IRF1 cis-reQTL was discovered in a previous immune-response eQTL study (Kim-
Hellmuth et al, 2017).  Briefly, primary monocytes were isolated from 134 donors and treated with 
LPS, MDP, IVT RNA, or no treatment. To assess early and late immune response, RNA expression 
was measured with a microarray chip after 90 min and 6 h.  To detect a significant cis-reQTL, the 
effect size b of association between genotype and expression of genes were compared between 
untreated and treated samples.  rs17622517 was found to be a significant cis-reQTL variant for 
IRF1 at 90m after LPS treatment, i.e. under early immune stimulus. 
Trans-eQTL discovery was done with the MatrixEQTL R package, performing a linear 
regression between the genotype of the top variant for each of the 126 significant cis-reQTL at 
LPS 90 min and all expressed probes in monocytes at 6 hours (22,657).  Benjamini-Hochberg 
correction was performed across p-values for all variants and probes. A significance threshold of 
FDR < 0.5 was used for downstream analyses. Since rs17622517 was found to be associated with 
many genes in trans at 6 hours, in addition to the cis association with IRF1, it was selected for 
further follow up.  
 
Enrichment of IRF1 targets 
IRF1 targets were obtained from the molecular signatures database (MSigDB) gene set 
IRF1-01, which comprises genes which contain at least one IRF1 motif in the 4kb upstream and 
downstream from their transcription start site (Liberzon et al., 2011). Trans-eGenes from the 
rs17622517 trans-eQTL (FDR < 0.5) and CRISPRi differentially expressed gene set (FDR < 0.05) 
were tested for enrichment in IRF1 target genes using a Fisher’s exact test comparing the number 
of genes in the set which overlap IRF1 target genes with the number of background expressed 
genes which overlap IRF1 targets.  




 HEK293/hTLR4A-MD2-CD14 Cells (Invivogen) were selected for functional follow up 
of the IRF1 trans-eQTL because of the ease of transfection of HEK293 cells and the addition of 
the TLR4 receptor, which is essential for cellular response to LPS. Cells were cultured in DMEM 
supplemented with 4.5 g/l glucose (Corning), 10% fetal bovine serum (Sigma-Aldrich), 1% 
penicillin/ streptomycin (Corning) and 1% L-glutaMAX (gibco). Cells were passaged using cell 
scraping to avoid damaging the cell surface receptors. 
 
CRISPRi of IRF1 promoter and enhancer locus  
 In order to determine whether the region of the eQTL variant regulates IRF1, and the effect 
of IRF1 perturbation in our cell line, we performed CRISPRi experiments targeting both the variant 
locus and the IRF1 promoter.  HEK293-TLR4 cells were plated in three 24-well plates with 120K 
cells/well in 1ml of DMEM. 24 hours later, the medium was replaced with 0.5ml of OptiMem 
(Gibco) and cells were transfected with 1.5ul of lipofectamine 3000 (Thermo Fisher Scientific), 
200ng of CRISPR-KRAB-MeCP2 vector (Addgene 110821) and 50 ng of gRNA gblock (IDT) (4 
wells each received a gRNA targeting EGFP as a neutral control 
(‘GGTGGTGCAGATGAACTTCA’), 14 bp downstream of the IRF1 promoter 
(‘GTCTTGCCTCGACTAAGGAG’) or the enhancer (‘TTCTCTGTAGCCCTTGTATT’)). After 
28 hours, 1ug/mL of LPS (Invivogen)was added to the 90 m and 12 h samples and nothing to the 
control samples, with four biological replicates of each gRNA for each LPS treatment (36 total 
samples). Cells were collected at their respective timepoint with TRIzol reagent (Thermo Fisher 
Scientific) and stored at -80C before RNA extraction.  




 In order to validate the cis and trans reQTL associations of rs17622517, we edited the 
HEK293-TLR4 cells using CRISPR/Cas9 genome editing.  A gRNA 
(‘TTCTCTGTAGCCCTTGTATT’) was designed with an NGG pam and a cut site 1 bp 
downstream from rs17622517.  The gRNA was ordered as a single stranded oligo gblock from 
IDT and amplified using 2 50 uL reactions of Q5 High Fidelity 2X Master Mix (NEB). Cells were 
transfected with 0.5 ug gRNA gblock and 2.5 ug px458 plasmid (Addgene plasmid # 48138) 
containing spCas9 and GFP with lipofectamine 3000 (Thermo Fisher Scientific). 24-hours later, 
cells then underwent fluorescence-activated cell sorting for GFP+ cells using a Sony SH800Z cell 
sorter to enrich for transfected cells. Efficiency of editing was tested using a T7E1 assay and 
electrophoresis gel to detect presence of NHEJ.  The GFP+ cells were also sorted as single cells 
into 15 96-well plates and expanded into monoclonal cell lines.   
Clones were genotyped by creating an amplicon library for each clone from gDNA using 
nextera primers capturing a 218 bp amplicon containing the variant locus. Indexing PCR was 
performed next using primers specific to the constant sequence on the nextera primers, resulting 
in dual-barcoded amplicons with illumina adapters.  Libraries were mixed in equal volume and 
sequenced on the MiSeq using 150 bp paired-end reads.  Fastq files generated by the Illumina 
software were trimmed for adapter sequences and quality using trimmomatic. Reads were aligned 
to the genomic locus and categorized as no edit or NHEJ using Edityper (Yahi et al. In prep). Since 
the cell line is triploid at this genomic locus, clones were considered heterozygous if they had 
NHEJ between 20-70%.  Clones with less than 10% NHEJ were considered wild type and clones 
with greater than 90% NHEJ were considered homozygous edited. Five each of wild type, 
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heterozygous and homozygous edited were selected for follow up. BAM files from the selected 
clones were also visually inspected to confirm genotype. In addition, a 3,496 bp PCR followed by 
electrophoresis gel was performed on the clones in order to check for larger indels not captured by 
the shorter amplicon libraries. 
 
LPS treatment of edited clones 
To detect the reQTL effect of the edited locus, we performed LPS treatment followed by 
RNA-sequencing on each isolated edited and wild type cell line. Each clonal cell line was plated 
into three wells (one well each for control, 90m and 12h treatments) in 24-well plates with 180,000 
cells per well. 24 hours later, 1ug/mL of LPS (Invivogen) was added to the 90 m and 12 h samples. 
RNA was extracted at the designated timepoint by adding 500 uL of IBI Isolate DNA/RNA 
Reagent (IBI Scientific) directly to cells on the plate and stored at -80C until extraction.  
 
RNA extraction and RNA-seq library preparation 
RNA was extracted following the Direct-zol RNA MicroPrep kit (Zymo Research) 
manufacturer’s instructions. RNA was treated with DNAse I (Ambion) and enriched for mRNA 
using Dynabeads mRNA DIRECT Purification Kit (Thermo Fisher).  cDNA was generated using 
a custom scaled-down modification of the SMART-seq protocol (Picelli et al., 2014). cDNA was 
synthesized from RNA input using Maxima H Minus Reverse Transcriptase (Thermo Fisher 
Scientific). It was then amplified using Kapa HiFi 2X Ready Mix (Kapa Biosystems). cDNA was 
then cleaned using 0.9X Ampure beads.  Finally, cleaned cDNA samples were tagmented and 
indexed using the Nextera XT DNA Library Prep Kit (Illumina). Library size and tagmentation 
was confirmed using the TapeStation HS D1000 kit (Agilent).  Libraries were pooled in equal 
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 Reads were first trimmed of adapters using trimmomatic, then aligned to the hg19 genome 
using STAR 2-pass mapping. Gene counts were calculated with FeatureCounts using gencode v19 
gene annotations.   
 
Differential expression analysis 
  For analysis of the effects of CRISPRi on the transcriptome, a count matrix was 
created in R from the raw counts of all samples. Principal component analysis was performed on 
the count matrix, after transformation and normalization with vst(). Differential expression was 
performed using an interaction model (~gRNA + condition + gRNA:condition) with DESeq2. 
Prior to p-value correction, genes were discarded if they did not have an average expression of 
greater than 5 read counts across samples and an annotation of protein coding or lncRNA in 
gencode. P-values for differential expression were corrected using Benjamini-Hochberg correction 
and a 5% FDR significance threshold was used.  
For analysis of the effect of CRISPR editing the variant locus, a count matrix was created 
in R from the raw counts of all samples. Since library prep and RNA-Seq were performed twice, 
the count matrices from the two runs were summed together. Differential expression analysis was 
performed using the R package DEseq2 using a nested interaction model (expression ~ genotype 
+ genotype:clone + genotype:condition) accounting for the same clone being found in each 
treatment group and testing for differential expression in the interaction between condition and 
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genotype. Prior to p-value correction, genes were discarded if they did not have an average 
expression of greater than 5 read counts across samples and an annotation of protein coding or 
lncRNA in gencode. P-values for differential expression were corrected using Benjamini-
Hochberg correction and a 5% FDR significance threshold was used.  
Enrichment analysis on significantly differentially expressed genes was done using 
DAVID biological process gene ontology enrichment, using Benjamini-Hochberg corrected p 
values and 5% false discovery rate. 
 
Comparison between edited clone and CRISPRi differential expression 
For comparison of the differential expression fold changes between the edited clonal RNA-
seq and the CRISPRi RNA-seq experiments, the genes in the edited differential expression analysis 
with an FDR of 25% were intersected with the genes in the CRISPRi differential expression 
analysis and a Spearman correlation test was performed. 
 
Trans-reQTL comparison to differential expression of edited clones and CRISPRi samples 
Some of the expression probes in the monocyte study measure the same gene. Therefore, 
the mean beta from the trans-eQTL study for probes overlapping the same gene was taken. The 
intersection of this gene list and the genes tested for differential expression was obtained. A 
Spearman correlation test was performed on the trans-reQTL betas and fold changes from 
DESeq2.  
Results 
Top variant for IRF1 cis-reQTL is in a likely enhancer  
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In the cis-reQTL study, the most significant variant for IRF1 expression 90 minutes after 
stimulation with LPS is rs17622517, which is the top variant associated with IRF1 expression 
under stimulation with LPS, but not at baseline (figure 3-1a). This variant is located about 23,000 
bp downstream of the IRF1 TSS in an intron of the gene C5ORF56. There are other neighboring 
variants which are significantly associated with IRF1 expression as well (figure 3-1b). However, 
the genomic context of rs17622517 lends further support to its causality. In ENCODE DNase 
hypersensitivity assays, this locus overlaps a peak in many cell types, including monocytes 
(Thurman et al., 2012). Furthermore, ENCODE H3K27Ac ChIP-Seq in the GM12878 cell line, a 
lymphoblastoid cell line, suggests an active immune cell enhancer in this region (pink peaks in 
H3K27Ac track in figure 3-1c). Finally, ENCODE transcription factor ChIP-Seq data also show 
significant peaks at this locus for many transcription factors in lymphoblastoid cell lines (figure 3-
1c). These include IRF4, another interferon regulatory factor, and RELA, a subunit of NF-κB, a 
key regulator in TLR4 signaling. Additionally, this variant has been found as a hit in a GWAS for 
chronic inflammatory diseases: ankylosing spondylitis, Crohn's disease and ulcerative colitis 
(Ellinghaus et al., 2016), lending further support for its involvement in immunity. 
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Figure 3-1. rs17622517 is the top variant associated with the IRF1 cis- and trans- reQTL under LPS 
stimulation. (a) cis-reQTL boxplots demonstrating IRF1 expression versus genotype of rs17622517 in 
monocytes harvested from 132 individuals at baseline, 90 min and 6 hours after LPS stimulation. (b) 
LocusZoom plot of the IRF1 cis-reQTL, highlighting top variant rs17622517. (c) UCSC genome browser 
view of top variant rs17622517, demonstrating overlap with transcription factor binding, DNase 
hypersensitivity and H3K27Ac peaks. The red line shows the variant location. (d) The number of gene 
expression probes (y-axis) associated with cis-eQTL top variant (x-axis) at FDR 0.5 for those cis-eQTL 
variants with greater than one trans association. IRF1 top cis-eQTL variant rs17622517 is highlighted in 
orange. 
 
IRF1 cis-reQTL variant is a significant trans-reQTL for many target genes 
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The top variants for all 126 of the significant cis-reQTLs at LPS 90 min from Kim-
Hellmuth, et al. was tested for association with the expression of all 22,657 expressed probes in 
monocytes. The IRF1 variant is associated with 232 expression probes with a lenient FDR 
threshold of 0.5 (table 3-3), substantially more than the other cis-reQTLs (figure 3-1d). These 
results suggest that the IRF1 variant acts as a master regulator trans-eQTL to modify expression 
of many genes. The FDR 0.5 trans-eQTL genes are enriched for MSigDB IRF1 target genes, 
defined as having an IRF1 motif within 4 kb of their TSS (Fisher test p = 1.8e-4). These trans-
reQTLs are mostly not detected until 12 hours after LPS stimulation (figure 3-2a), suggesting a 
sequential expression effect with the cis-eQTL detectable at 90 minutes and the trans-eQTL 
detectable at 12 hours. This timing is consistent with the hypothesis that the cis-eQTL affects 
expression of IRF1 first, which then affects the expression of downstream direct and indirect 
targets of IRF1. With a more stringent FDR threshold of 0.05, the IRF1 variant is associated with 
12 trans-eGenes, all but one of which have higher expression in individuals with the alternative 
allele (figure 3-2b), which is the same direction as the cis-eQTL. The discovery of the vast number 
of trans-associations for this variant inspired the next part of this study: replicating the trans-
reQTL for IRF1 experimentally.  
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Figure 3-2. The trans-association for rs17622517 is detectable 6 hours after LPS stimulation, after 
the 90 min cis-eQTL for IRF1. (a) Beta of association with rs17622517 for the 216 trans-reQTLs (FDR 
0.5) at baseline, 90 min and 6 hours after LPS stimulation. (b) Boxplots for the 12 significant trans-reQTLs 
(FDR 0.05) showing expression of trans-eGenes versus genotype of rs17622517 6 hours after LPS 
stimulation. 
 
IRF1 enhancer locus appears to be an active enhancer in HEK-TLR4 cells  
 In order to investigate the effect of repressing the enhancer in which the IRF1 eQTL SNP 
is located, we transfected a gRNA at the variant locus along with a dCas9-KRAB-MeCP2 vector 
in HEK-TLR4 cells. In this CRISPRi system, the dCas9 enzyme is guided to the genomic locus of 
interest by the gRNA but lacks the enzymatic capacity for inducing double stranded breaks and is 
coupled to KRAB-MeCP2, a repressor which has been shown to strongly decrease expression of 
proximal genes (Yeo et al., 2018).  To test the effect of repressing expression of IRF1 under LPS 
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the dCas9-KRAB-MeCP2 vector (schematic in figure 3-3a). Additionally, we included a gRNA 
targeting EGFP as a control. After transfection with CRISPRi constructs, we treated four replicates 
of each transfection with LPS for 0h, 90m or 12h. We then performed RNA-sequencing on the 36 
samples (3 gRNAs x 3 LPS conditions x 4 replicates) and mapped reads to known genes.  
 Upon principle component analysis, samples tend to cluster both by LPS condition, 
captured in principal component 1, and gRNA, captured in principal component 2 (figure 3-3b). 
This result suggests that both promoter and enhancer gRNAs are inducing strong effects on the 
transcriptome. When we look at the expression of IRF1 across samples, we see significantly higher 
IRF1 expression in LPS 90m samples (Wilcoxon p = 0.024) and LPS 12h samples (Wilcoxon p = 
0.038) as compared to 0h samples. Additionally, we see a strong repression of IRF1 in the promoter 
gRNA samples across LPS conditions as compared to the control (Wilcoxon p = 7.4x10-7, figure 
3-3c), indicating a successful repressive effect of the promoter gRNA. The enhancer gRNA 
samples do not have significantly different IRF1 expression than the controls (Wilcoxon p = 0.8), 
but it is not expected to have as large of an effect as in the promoter gRNA.   
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Figure 3-3. RNA-sequencing of hTLR4 cells with CRISPRi targeting IRF1 promoter and rs17622517 
supports causality of the variant locus. (a) Schematic of the promoter (orange) and enhancer (purple) 
gRNAs guiding dCAS9-KRAB-MeCP2 to their respective genomic loci. (b) PCA plots of normalized 
RNA-sequencing counts coloring samples by LPS condition and CRISPRi gRNA. (c) IRF1 expression in 
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Next, we performed differential expression analysis on the gene counts from the RNA-seq 
of the 36 samples to detect the transcriptional effect of LPS, silencing of the enhancer and the IRF1 
promoter and the interaction between the two. First, we looked at the effect of LPS treatment in 
control gRNA samples using a model of differential expression between the LPS conditions. The 
90m LPS versus 0h effect includes 30 differentially expressed genes with an FDR of 0.05. The top 
enriched GO terms for this set of genes are inflammatory response (corrected p-value = 5.6x10-8), 
chemokine-mediated signaling pathway (corrected p-value = 1.7x10-5) and response to LPS 
(corrected p-value = 7.4x10-4). The 12h versus 0h effect includes 476 differentially expressed 
genes. The top enriched GO terms for this set of genes are inflammatory response (corrected p-
value = 1.9x10-5), cell-cell signaling (corrected p-value = 8.0x10-3), chemokine-mediated signaling 
pathway (corrected p-value = 8.5x10-3) and NF-kB signaling (corrected p-value = 1.1x10-2). 
Between these two sets of differentially expressed genes, 22 genes overlap. This result 
demonstrates that the TLR4 cells are responding to LPS stimulation by activating pro-
inflammatory cellular pathways.  
The promoter versus control effect, using a model of differential expression between 
gRNAs in 12h LPS samples, includes 1016 genes. The enriched terms for this gene set fall into a 
broad spectrum of cellular processes (table 3-1), perhaps due to the large range of functions of 
IRF1 in the cell. The 19th highest enriched GO term for this set of genes is NF-kB signaling 
(corrected p-value = 3.2x10-4). The enhancer versus control main effect includes 225 genes. 
Interestingly, 161 of these enhancer differentially expressed genes are also differentially expressed 
under the promoter gRNA, suggesting that the enhancer effects on the transcriptome are primarily 
mediated by IRF1. Among other cellular processes (table 3-2), this set of enhancer differentially 
expressed genes is enriched for MyD88-independent TLR signaling pathway (p-value = 9.4x10-4), 
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NF-kB signaling (corrected p-value = 7.3x10-3), TRIF-dependent TLR signaling pathway 
(corrected p-value = 0.015), MyD88-dependent toll-like receptor signaling pathway (corrected p-
value = 0.02). The MyD88 and TRIF-dependent pathways are the two parallel pathways triggered 
by LPS binding and TLR4 activation. These enrichments suggest that repression of the enhancer 
affects the immune cell’s response to LPS. Neither enhancer nor promoter differentially expressed 
gene lists were significantly enriched for msigdb IRF1 targets (Fisher test p = 1 and 0.245, 
respectively).  
Finally, we used a ~gRNA + condition + gRNA:condition model to capture the interaction 
effects of gRNA and LPS condition. We see very few significant genes for the interaction effect 
between gRNA and LPS condition: 2 genes for promoter:condition90m, 15 for 
enhancer:condition90m, 1 for promoter:condition12h and 17 for enhancer:condition12h. We 
hypothesize that perhaps we are underpowered to detect subtle interaction effects. Nevertheless, 
due to the large number of genes whose expression is affected by the enhancer CRISPRi, and high 
overlap between these genes and the genes affected by the IRF1 promoter CRISPRi, we felt 
confident that the enhancer is active in these cells and the causality of the lead cis- and trans-eQTL 
variant is worth pursuing.  
 
Table 3-1. Promoter versus control enriched GO terms in differentially expressed genes in 12h LPS samples 




protein targeting to membrane 68 6.7 1.73E-63 13.2 5.21E-60 
viral transcription 68 6.7 1.12E-55 11.1 1.68E-52 
translational initiation 73 7.2 2.95E-54 9.7 2.96E-51 
nuclear-transcribed mRNA catabolic 
process, nonsense-mediated decay 67 6.6 7.60E-52 10.3 5.72E-49 
rRNA processing 79 7.8 6.57E-44 6.7 3.96E-41 
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translation 81 8.0 9.27E-40 5.8 4.65E-37 
mitochondrial electron transport, 
NADH to ubiquinone 18 1.8 3.72E-10 6.7 1.60E-07 
cell-cell adhesion 42 4.2 2.91E-09 2.8 1.10E-06 
mitochondrial respiratory chain 
complex I assembly 19 1.9 4.04E-09 5.5 1.35E-06 
ribosomal small subunit assembly 11 1.1 1.34E-08 10.6 4.02E-06 
mitochondrial electron transport, 
cytochrome c to oxygen 11 1.1 2.54E-08 10.0 6.96E-06 
cytoplasmic translation 12 1.2 2.70E-08 8.8 6.77E-06 
cell division 47 4.6 2.99E-08 2.5 6.92E-06 
mitochondrial ATP synthesis 
coupled proton transport 11 1.1 4.61E-08 9.6 9.93E-06 
positive regulation of ubiquitin-
protein ligase activity involved in 
regulation of mitotic cell cycle 
transition 18 1.8 5.42E-07 4.3 1.09E-04 
mitotic nuclear division 35 3.5 7.08E-07 2.6 1.33E-04 
anaphase-promoting complex-
dependent catabolic process 18 1.8 9.70E-07 4.2 1.72E-04 
negative regulation of ubiquitin-
protein ligase activity involved in 
mitotic cell cycle 17 1.7 1.05E-06 4.4 1.75E-04 
NIK/NF-kappaB signaling 16 1.6 2.02E-06 4.4 3.20E-04 
proteasome-mediated ubiquitin-
dependent protein catabolic process 29 2.9 5.93E-06 2.6 8.92E-04 
positive regulation of canonical Wnt 
signaling pathway 21 2.1 7.51E-06 3.2 1.08E-03 
ribosomal small subunit biogenesis 8 0.8 1.06E-05 9.1 1.44E-03 
ATP biosynthetic process 10 1.0 1.56E-05 6.3 2.04E-03 
protein polyubiquitination 26 2.6 2.39E-05 2.6 3.00E-03 
stimulatory C-type lectin receptor 
signaling pathway 18 1.8 5.22E-05 3.1 6.27E-03 
viral process 34 3.4 9.91E-05 2.1 1.14E-02 
DNA damage response, detection of 
DNA damage 10 1.0 1.04E-04 5.1 1.15E-02 
Wnt signaling pathway, planar cell 
polarity pathway 16 1.6 1.31E-04 3.2 1.40E-02 
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antigen processing and presentation 
of exogenous peptide antigen via 
MHC class I, TAP-dependent 13 1.3 1.34E-04 3.8 1.38E-02 
regulation of mRNA stability 17 1.7 1.42E-04 3.0 1.42E-02 
error-prone translesion synthesis 7 0.7 3.85E-04 6.7 3.67E-02 
hydrogen ion transmembrane 
transport 12 1.2 4.15E-04 3.6 3.83E-02 
covalent chromatin modification 17 1.7 4.22E-04 2.7 3.78E-02 
cellular response to DNA damage 
stimulus 25 2.5 4.44E-04 2.2 3.85E-02 
 
Table 3-2. Enhancer versus control enriched GO terms in differentially expressed genes in 12h LPS 
samples 




SRP-dependent cotranslational protein 
targeting to membrane 71 32.0 4.58E-119 62.8 4.94E-116 
viral transcription 70 31.5 6.50E-108 52.0 3.50E-105 
nuclear-transcribed mRNA catabolic 
process, nonsense-mediated decay 70 31.5 3.45E-105 48.9 1.24E-102 
translational initiation 70 31.5 3.30E-99 42.5 8.88E-97 
rRNA processing 70 31.5 2.37E-82 27.2 5.10E-80 
translation 72 32.4 6.52E-80 23.7 1.17E-77 
cytoplasmic translation 13 5.9 2.79E-17 43.2 4.30E-15 
ribosomal small subunit assembly 9 4.1 2.47E-11 39.4 3.33E-09 
cell-cell adhesion 21 9.5 9.39E-11 6.4 1.12E-08 
ribosomal small subunit biogenesis 8 3.6 3.31E-10 41.6 3.57E-08 
ribosomal large subunit assembly 8 3.6 3.20E-09 31.7 3.14E-07 
translational elongation 6 2.7 1.76E-06 27.7 1.59E-04 
virion assembly 5 2.3 9.15E-06 34.6 7.58E-04 
ribosomal large subunit biogenesis 6 2.7 1.02E-05 20.0 7.87E-04 
MyD88-independent toll-like receptor 
signaling pathway 5 2.3 1.31E-05 32.0 9.40E-04 
regulation of mRNA stability 9 4.1 3.30E-05 7.3 2.22E-03 
response to ethanol 9 4.1 3.79E-05 7.1 2.40E-03 
DNA damage response, detection of 
DNA damage 6 2.7 6.52E-05 13.9 3.90E-03 
error-prone translesion synthesis 5 2.3 6.71E-05 21.9 3.80E-03 
NIK/NF-kappaB signaling 7 3.2 1.36E-04 8.8 7.33E-03 
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negative regulation of ubiquitin-protein 
ligase activity involved in mitotic cell 
cycle 7 3.2 2.05E-04 8.2 1.05E-02 
positive regulation of ubiquitin-protein 
ligase activity involved in regulation of 
mitotic cell cycle transition 7 3.2 2.97E-04 7.7 1.45E-02 
TRIF-dependent toll-like receptor 
signaling pathway 5 2.3 3.26E-04 14.8 1.52E-02 
regulation of necrotic cell death 4 1.8 3.43E-04 27.7 1.53E-02 
intracellular transport of virus 6 2.7 3.51E-04 9.8 1.50E-02 
anaphase-promoting complex-dependent 
catabolic process 7 3.2 3.67E-04 7.4 1.51E-02 
regulation of tumor necrosis factor-
mediated signaling pathway 5 2.3 4.28E-04 13.9 1.69E-02 
regulation of type I interferon production 4 1.8 4.42E-04 25.6 1.69E-02 
viral life cycle 5 2.3 4.87E-04 13.4 1.79E-02 
maturation of SSU-rRNA from 
tricistronic rRNA transcript (SSU-rRNA, 
5.8S rRNA, LSU-rRNA) 5 2.3 5.51E-04 13.0 1.96E-02 
MyD88-dependent toll-like receptor 
signaling pathway 5 2.3 6.21E-04 12.6 2.14E-02 
I-kappaB kinase/NF-kappaB signaling 6 2.7 7.49E-04 8.3 2.49E-02 
regulation of protein ubiquitination 4 1.8 8.43E-04 20.8 2.72E-02 
translesion synthesis 5 2.3 8.70E-04 11.5 2.72E-02 
negative regulation of epidermal growth 
factor receptor signaling pathway 5 2.3 8.70E-04 11.5 2.72E-02 
DNA damage response, signal 
transduction by p53 class mediator 
resulting in cell cycle arrest 6 2.7 8.70E-04 8.0 2.65E-02 
nuclear import 4 1.8 1.21E-03 18.5 3.55E-02 
G2/M transition of mitotic cell cycle 8 3.6 1.32E-03 4.9 3.76E-02 
error-free translesion synthesis 4 1.8 1.42E-03 17.5 3.95E-02 
protein polyubiquitination 9 4.1 1.70E-03 4.1 4.60E-02 
 
Isolating monoclonal cell lines with edits at the IRF1 variant locus 
 In order to obtain cell lines to further investigate the IRF1 reQTL, we used CRISPR/Cas9 
genome editing to introduce indels at the variant’s genomic locus in HEK293-TLR4 cells. The 
experimental strategy is exhibited in figure 3-4a. Amplifying and sequencing gDNA from the 
polyclonal edited population revealed an editing efficiency of 31% NHEJ before sorting and 50% 
NHEJ after sorting GFP+ cells, the difference presumably explained by increased transfection 
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efficiency. Fifteen plates of monoclonal cell lines from the GFP+ sorted cells were screened for 
editing. Fifteen of those clones were expanded based on promising results from the monoclonal 
genotyping sequencing. Because the HEK293 cell line is triploid at this locus, clones are 
considered heterozygous if they have one or two edited alleles. Homozygous clones have all three 
alleles edited, and wild type clones show no edited alleles. Upon further inspection, clone 1-A4 
was eliminated from further study due to the fact that it has 50% of one deletion and 50% of 
another, suggesting it has lost an allele. Additionally, clone 2-B4 was eliminated due to long-range 
PCR producing multiple bands, suggesting large indels at the variant locus (figure 3-4b). The 13 
clones selected for functional follow-up include five homozygous reference (wild type) clones (not 
shown), three heterozygous clones, and five homozygous alternative clones (figure 3-4c).  
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Figure 3-4. Eight edited clones with small deletions at the rs17622517 variant locus and five wild type 
clones were obtained using CRISPR/Cas9 and single cell sorting. (a) Approach to edit and isolate single 
cell clones. A gRNA which cuts 1 bp from the rs17622517 variant is transfected as a gblock along with a 
CRISPR/Cas9 and GFP+ plasmid into HEK293-TLR4 cells.  GFP+ cells are then sorted into single wells 
of 96 well plates. Genotyping of the monoclonal cell lines is performed by next-generation amplicon 
sequencing using locus-specific primers and indexed nextera adapters. (b) Gel electrophoresis image of a 
3,496 bp PCR amplicon spanning the cut site to check for larger deletions or insertions in 15 expanded 
monoclonal cell lines. (c) The deletions in the three “heterozygous” and five “homozygous” edited clones 
chosen for LPS stimulation and RNA-seq, along with five wild type clones, not pictured. 
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Editing the enhancer locus results in differential expression which correlates with enhancer 
and promoter CRISPRi perturbation 
 Each of the 13 clones was exposed to three conditions: untreated, 90 min LPS treatment 
and 12 hours LPS treatment. The 12 hour timepoint was used instead of the 6 hour timepoint used 
in the monocyte study because previous experiments in the lab showed that genes involved in LPS 
response had a longer lag in response time in HEK293-TLR4 cells than in monocytes (data not 
shown). After treatment, RNA-sequencing was performed on the samples and reads were mapped 
to the genome and assigned to known genes. The stimulation and sequencing experiment was 
performed twice and the reads were combined for each sample, resulting in an average of 31.6 
million reads per sample. Principle component analysis of normalized gene expression 
demonstrates that samples separate strongly by treatment effect and slightly by genotype (figure 
3-5a). This is as expected, since LPS stimulation should elicit a strong response in these cells and 
the genotype effect is small and expected to only be active at the 12h timepoint.   
 Differential expression analysis of the RNA-sequencing samples revealed that many genes 
are differentially expressed between the 90m or 12h LPS and control samples (figure 3-5b). The 
DE gene lists for control vs 90m and 12h are enriched for gene ontology (GO) terms involved in 
inflammatory response and NF-kB signaling, signifying a successful stimulation of the samples. 
IRF1 expression is induced upon stimulation at 90m and 12h as compared to control (figure 3-5c), 
but IRF1 does not vary significantly between genotypes (Kruskal-Wallis p = 0.17, figure 3-5d). 
An effect of the edit on expression of genes would manifest as an interaction between genotype 
and condition, meaning edited clones differ in their transcriptional response to LPS stimulation 
than wild type clones. However, differential expression (DE) analysis on the interaction between 
genotype and condition did not result in meaningful significant genes, much like we saw with the 
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CRISPRi treatment. For the 12-hour timepoint, where we would expect to see the trans-eQTL 
effect, there were 37 DE genes (FDR 5%) between HO and HE clones, 0 genes between HO and 
WT and 3 DE genes between HE and WT. These DE genes have no overlap with IRF1 targets or 
trans-eGenes from the eQTL study, suggesting that it may be due to noise. This result is not 
necessarily surprising given the relatively low sample size and modest effects of trans-eQTLs. As 
in the CRISPRi differential expression, we hypothesized that perhaps the interaction effects of 
gRNA and LPS condition exist, but are subtle and their discovery is limited by power. 
In order to determine whether editing the variant locus results in a similar effect as the 
CRISPRi perturbation of the enhancer or promoter, we looked at the correlation between the 
differential expression fold changes in the edited cells and CRISPRi 12h differential expression 
fold changes. The correlation between the promoter interaction fold changes with the monoclonal 
edited HE vs HO fold changes in DE genes (FDR 0.25) is significant (rho = 0.21, p = 2.52x10-8, 
figure 3-5e), suggesting that editing the variant has a similar effect on these genes as a knockdown 
of IRF1 expression. We also see a significant correlation in this same set of genes between the 
enhancer interaction fold changes and the edited clone fold changes (rho = 0.22, p = 4.31x10-9 
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Figure 3-5. RNA-sequencing demonstrates an effect of editing the locus which correlates with the 
CRISPRi perturbations. (a) PCA plots of normalized RNA-sequencing counts coloring samples by 
condition and genotype. (b) Shared and unique significantly differentially expressed genes (5% FDR) 
between 90 min and control and 12 hour and control samples in WT clones along with the three top 
significantly enriched GO terms for each gene set from DAVID. (c) IRF1 expression in all clones split by 
condition and colored by individual clone identity. (d) IRF1 expression in all clones split by genotype for 
90 min samples. (e) Correlation between differential expression fold change between HE and HO edited 
clones and differential expression fold change between CRISPRi gRNA treatments (promoter vs control) 
for the same set of genes (HE vs HO DE genes at 0.25 FDR). (f) Correlation between differential expression 
fold change between HE and HO edited clones and differential expression fold change between CRISPRi 
gRNA treatments (enhancer vs control) for the same set of genes (HE vs HO DE genes at 0.25 FDR). 
 
IRF1 trans-eQTL effect sizes are correlated with differential expression fold change in edited 
clones 
 In order to investigate if and how the effect of the trans-eQTL can be captured by genome 
editing a cell line, we compared the effect size (beta) of association for the trans-eQTL eGenes at 
6 hours in the monocyte study with the fold changes from the differential expression, testing the 
interaction between genotype and condition for the same genes. The trans-eQTL betas are 
significantly positively correlated with the fold changes in WT/HE clones (figure 3-6a) and 
significantly negatively correlated with fold changes in HE/HO clones (figure 3-6b). The 
correlation between WT/HO fold changes and trans betas was not significant. The correlation 
finding here is strong evidence that the trans-eQTL is a true association, which is acting through 
a condition-specific active enhancer modifying the expression level of the IRF1 gene.  
 In order to see if the CRISPRi perturbation has a similar effect a the trans-eQTL 
associations, we also looked at the correlation of the fold changes in the 12h interaction differential 
expression with the betas of the IRF1 trans-eGenes from the monocyte study (filtered for FDR 
0.25). The correlations between promoter and enhancer interaction fold changes and trans-eGene 
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betas are not significant (figure 3-6c-d), suggesting a stronger similarity between CRISPR editing 
and the trans-eQTL effect than CRISPRi perturbation and the trans-eQTL effect. 
 
 
Figure 3-6. RNA-sequencing of the edited clones with and without LPS stimulation demonstrates a 
mild effect of genotype on the trans-eGenes for rs17622517. (a) Correlation between trans-reQTL effect 
sizes from the monocyte study and differential expression fold change between WT and HE clones for the 
same set of genes (trans-eGenes at 0.5 FDR). (b) Correlation between trans-reQTL effect sizes from the 
monocyte study and differential expression fold change between HE and HO edited clones for the same set 
of genes (trans-eGenes at 0.5 FDR). (c) Correlation between trans-reQTL effect sizes from the monocyte 
study and differential expression fold change between promoter CRISPRi and control gRNA treatments at 
c. d.
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12h for the same set of genes (trans-eGenes at 0.5 FDR). (d) Correlation between trans-reQTL effect sizes 
from the monocyte study and differential expression fold change between enhancer CRISPRi and control 
gRNA treatments at 12h for the same set of genes (trans-eGenes at 0.5 FDR).  
Discussion 
In this study, we discovered an immune-response eQTL which is significant not only for 
one gene IRF1 in cis, but also many other genes in trans.  Trans-eQTLs in general are difficult to 
detect, in part because of the multiple testing burden of testing each variant against all genes, 
generally smaller effect sizes, context-specificity and other technical factors (Saha and Battle, 
2018; Võsa et al., 2018). We increased the FDR threshold to 0.5 in order to further investigate the 
trans associations, something that is not unusual in trans-eQTL studies. The much higher number 
of IRF1 trans-eGenes as compared to the other cis-eQTLs as well as the enrichment of IRF1 targets 
in those trans-eGenes lends strong support for the trans-eQTL’s validity.  
We used a CRISPR-based approach to analyze this trans-eQTL in a cellular model. After 
establishing that our HEK293-TLR4 cell line has a robust response to LPS, we verified with 
CRISPRi that silencing of the enhancer affects many genes, demonstrating that the eQTL variant 
locus is an active enhancer in these cells. Next, we demonstrated that genetic disruption of this 
eQTL variant locus impacts the expression of IRF1 targets in a condition-specific manner, and 
these effects are correlated with the CRISPRi silencing of the enhancer and the effect sizes of the 
trans-eQTLs. These results provide strong experimental support for the trans-eQTL.  
The CRISPRi experiments to perturb both the IRF1 promoter and the enhancer locus 
further support the idea that IRF1 plays a role in LPS response. The effect of the enhancer gRNA 
on many genes demonstrates that it is in fact active in these cells. The differential expression in 
promoter and enhancer are not significantly correlated with the trans-eGenes, which would have 
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further validated the trans-eQTL effect. However, IRF1 is known to affect different genes in many 
different cellular contexts and it is likely that its effect in this cell line may differ from that in 
primary monocytes. Nevertheless, the positive correlation between the enhancer CRISPRi 
differential expression and the monoclonal edited differential expression confirms that by 
inactivating the enhancer with CRISPRi, we are mimicking the effect of the edited variant. 
Furthermore, correlation between the promoter CRISPRi differential expression and the 
monoclonal edited differential expression indicates that the edited variant is acting through 
affecting transcription of IRF1.  
Differential expression analysis between the different genotypes of the monoclonal cell 
lines under stimulation did not detect the expected effect of editing the variant on expression of 
the trans-eGenes or IRF1. One explanation for this result is that we are underpowered to detect 
subtle changes in gene expression. eQTL studies require hundreds of subjects for this reason: 
regulatory effects can be small and noise due to smaller sample sizes can obscure true associations. 
In our case, perhaps the modest number of edited clones was not sufficient to detect the subtle 
effects of the variant. As we saw with the eliminated clone in figure 3-3b, monoclonal cell lines 
can have undetected large insertions or deletions which can introduce additional noise into the 
system. Additionally, we introduced a deletion into the variant locus, rather than introducing the 
exact variant into the cell line. If the variant somehow increases the activity of the enhancer, it is 
possible that deleting a portion of the enhancer does not replicate this effect, and that different 
deletions have different effects. We took this approach instead of introducing the variant with 
homologous recombination because of the extremely low HDR efficiency when we included a 
ssDNA template in the transfection. Optimizing the CRISPR and transfection conditions in these 
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cells could potentially increase editing efficiency and allow for isolation of monoclonal cell lines 
with the precise variant edited.   
In both the monoclonal editing and CRISPRi RNA-sequencing experiments, we do not see 
a perfect correlation of differentially expressed genes with the trans-eQTL effects. One explanation 
is that the trans-eQTL association was detected in primary patient-derived monocytes, while the 
CRISPRi silencing and variant editing was performed in a HEK cell line transduced with a hTLR4 
receptor. It is not surprising that the cell line does not fully recapitulate the trans-eQTL effect, 
since it may lack expression of other immune-related genes which may be interacting with IRF1. 
For example, IRF1 has been found to cooperate with  STAT1 (Abou El Hassan et al., 2017) in 
inducing expression of target genes. Furthermore, it is likely that the trans-eQTL genes are 
composed not only of direct targets of IRF1, but also downstream targets of IRF1 targets. If these 
genes are not as inducible in this cell line as in monocytes, these downsteam effects will be 
dampened. Another drawback to the cell line could be that it lacks expression of a protein which 
introduces a post-translational modification on IRF1, which affects its transcriptional activity. 
While research is unclear on the importance of post-translational modifications on IRF1, recent 
evidence suggests ubiquitination and phosphorylation may affect its activity (Garvin et al., 2019). 
Perhaps introducing variants into a monocyte cell line, such as THP1 cells, would benefit from a 
more robust immune response and therefore a larger effect of the enhancer perturbation. However, 
there are likely to be limitations to using any immortalized cell line. A future avenue of study could 
be introducing the variant into a mouse line and studying the LPS response in edited and wild type 
mouse-derived monocytes, as well as cytokine production in the mice in response to LPS.  
Our model for the regulatory action of the variant is that it affects the activity of the 
enhancer in which it resides, likely by changing the affinity for binding of a TF that may be active 
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only under LPS stimulus. This genetic effect on activity of the enhancer in turn affects expression 
of IRF1 under stimulation with LPS. The results of this study suggest that the IRF1 TF plays a role 
in regulating the transcriptional response of immune cells to LPS stimulation, and that a common 
genetic variant leads to inter-individual variation in this response. The alternative allele of this 
variant has additionally been found to be associated with ankylosing spondylitis, Crohn's disease 
and ulcerative colitis in a GWAS for chronic inflammatory diseases (Ellinghaus et al., 2016). 
Further support for IRF1 being plausibly involved in these diseases comes from the connection 
between known ulcerative colitis-related genes and IRF1. For example, ulcerative colitis has also 
been linked to IRF1 targets genes CXCL10 (Shi et al., 2019), IL6 (Wu et al., 2014) and iNOS (Wu 
et al., 2014) and IRF1-cooperating transcription factor STAT1 (Ciorba et al., 2010). Further 
experiments to explore the link between IRF1 and these diseases could include observing whether 
a knockdown of IRF1 or the enhancer locus in an animal model of ulcerative colitis improves the 
disease symptoms. 
In the cis-reQTL study, IRF1 does not have a significant cis-eQTL at baseline. It is only 
under stimulation with LPS that the regulatory effect of the variant is revealed. Therefore, the IRF1 
locus exemplifies the utility of introducing a cellular perturbation in order to detect variants 
involved not necessarily in baseline expression of genes, but dynamic expression of genes in 
different physiological contexts. Additionally, the top variant for this eQTL is found within an 
intron of another gene, C5ORF56. Therefore, when the variant was found as a hit in the 
inflammatory disease GWAS, it was automatically assigned to this gene, based on proximity. The 
results of the eQTL association for this variant suggest that the gene of interest might actually be 
IRF1, located 20 Kb away. The variant might be contributing to disease by modifying the 
expression of IRF1 and its targets and therefore modifying the immune-response in the individual. 
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This finding further exemplifies the usefulness of integrating eQTL data with GWAS in order to 
match variant-gene combinations. Although more follow up on the variant and enhancer is needed, 
this study has identified a genetic variant which modifies individuals’ response to immune 
stimulation by affecting an enhancer for IRF1 and the downstream regulatory pathways of IRF1 
in an immune stimulus -specific manner, suggesting that this is the likely mechanism for the 
genetic risk for autoimmune disease driven by this locus.  
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Table 3-3.  Trans-reQTL associations in monocytes for rs17622517 6 hours after stimulation with 
LPS (0.5 FDR). 
Illumina probe gene symbol trans-eQTL beta trans-eQTL p-value trans-eQTL FDR 
ILMN_1811378 GTPBP1 0.2 3.68E-08 0.001 
ILMN_1670000 DCAF6 -0.27 6.67E-08 0.002 
ILMN_1756862 APOL3 0.84 2.61E-07 0.008 
ILMN_2404512 PSEN2 0.24 2.80E-07 0.008 
ILMN_1701613 RARRES3 0.35 3.37E-07 0.01 
ILMN_1700671 ETV7 0.28 4.24E-07 0.012 
ILMN_1809467 VAMP5 0.47 8.16E-07 0.021 
ILMN_1690241 BATF2 0.37 1.03E-06 0.026 
ILMN_3307659 SFT2D2 0.38 1.61E-06 0.04 
ILMN_2373831 BTN3A3 0.25 1.79E-06 0.043 
ILMN_1670305 SERPING1 0.5 2.03E-06 0.047 
ILMN_1778599 SP140 0.25 2.09E-06 0.048 
ILMN_1768433 CCDC71 0.2 2.41E-06 0.055 
ILMN_1669617 GRB10 0.2 3.04E-06 0.068 
ILMN_1718558 PARP12 0.41 3.00E-06 0.068 
ILMN_2284998 SP100 0.36 3.23E-06 0.072 
ILMN_1808148 SMCHD1 0.15 3.73E-06 0.081 
ILMN_2233783 CD38 0.82 4.08E-06 0.086 
ILMN_1764380 GLTP -0.34 4.78E-06 0.096 
ILMN_1783843 MIIP 0.24 4.82E-06 0.096 
ILMN_2395236 CHEK2 0.19 5.27E-06 0.103 
ILMN_1668378 SFT2D2 0.18 5.38E-06 0.105 
ILMN_2373177 PANK2 0.24 5.44E-06 0.105 
ILMN_1771921 HSCB 0.23 6.39E-06 0.117 
ILMN_3237462 IDO2 0.23 6.87E-06 0.12 
ILMN_1805201 PML 0.18 6.86E-06 0.12 
ILMN_1690921 STAT2 0.46 7.11E-06 0.121 
ILMN_1753758 IL27 0.86 7.41E-06 0.124 
ILMN_1703263 SP140 0.34 7.88E-06 0.129 
ILMN_1749372 GGT5 0.24 8.00E-06 0.13 
ILMN_2296950 APOBEC3F 0.22 8.25E-06 0.132 
ILMN_1776602 ANG 0.2 8.55E-06 0.135 
ILMN_1710726 APOBEC3F 0.24 8.76E-06 0.137 
ILMN_1662964 PRMT3 -0.27 8.85E-06 0.138 
ILMN_3204136 LOC100132707 0.1 9.04E-06 0.14 
ILMN_1687533 SEMA4D 0.51 9.26E-06 0.142 
ILMN_1757845 SPIRE1 -0.26 9.42E-06 0.143 
ILMN_3238326 RNF144A 0.15 9.45E-06 0.143 
ILMN_1780831 SLC6A12 0.32 9.63E-06 0.144 
ILMN_1731299 PML 0.11 1.01E-05 0.151 
ILMN_1782487 GBP1 0.69 1.06E-05 0.153 
ILMN_1691393 DNPEP 0.19 1.06E-05 0.153 
ILMN_2148785 GBP1 0.65 1.05E-05 0.153 
ILMN_1727271 WARS 0.51 1.07E-05 0.154 
ILMN_1683178 JAK2 0.44 1.13E-05 0.161 
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ILMN_1797191 KIAA0040 0.2 1.20E-05 0.166 
ILMN_2183510 MANF 0.29 1.23E-05 0.167 
ILMN_2337655 WARS 0.43 1.24E-05 0.167 
ILMN_1728224 OGFR 0.35 1.26E-05 0.168 
ILMN_1788017 HSH2D 0.27 1.28E-05 0.171 
ILMN_1742929 HESX1 0.42 1.30E-05 0.173 
ILMN_1662026 BTK 0.26 1.34E-05 0.176 
ILMN_1659960 NUP62 0.45 1.34E-05 0.176 
ILMN_1692168 UBE2Z 0.27 1.37E-05 0.178 
ILMN_1726769 CNDP2 0.34 1.44E-05 0.184 
ILMN_1678766 DYNLT1 0.45 1.44E-05 0.184 
ILMN_1665865 IGFBP4 0.36 1.47E-05 0.187 
ILMN_1701114 GBP1 0.7 1.52E-05 0.19 
ILMN_1790472 SLC25A28 0.48 1.53E-05 0.191 
ILMN_1704477 COX5A -0.29 1.60E-05 0.198 
ILMN_1786612 PSME2 0.35 1.71E-05 0.207 
ILMN_2106725 NCF1B 0.26 1.72E-05 0.207 
ILMN_1751079 TAP1 0.38 1.72E-05 0.208 
ILMN_1721411 PARP10 0.46 1.77E-05 0.212 
ILMN_1731044 NDUFC2 0.26 1.89E-05 0.217 
ILMN_2325338 APOL2 0.27 1.90E-05 0.217 
ILMN_1665682 IL15RA 0.49 1.87E-05 0.217 
ILMN_1784320 ELMO1 0.32 1.89E-05 0.217 
ILMN_1813455 SP110 0.43 2.02E-05 0.219 
ILMN_1670572 IDO2 0.33 2.03E-05 0.219 
ILMN_1769143 KCNE2 0.12 2.01E-05 0.219 
ILMN_2355168 MGST1 -0.46 1.97E-05 0.219 
ILMN_1740572 TCN2 0.2 1.97E-05 0.219 
ILMN_1806017 PSME1 0.23 2.15E-05 0.229 
ILMN_1697409 TNFRSF14 0.27 2.18E-05 0.231 
ILMN_2349061 IRF7 0.52 2.26E-05 0.234 
ILMN_1771385 GBP4 0.77 2.29E-05 0.237 
ILMN_1725700 MOV10 0.44 2.32E-05 0.238 
ILMN_1713285 NAPA 0.24 2.34E-05 0.239 
ILMN_1738704 TRIM26 0.25 2.58E-05 0.254 
ILMN_2289093 RNF213 0.49 2.54E-05 0.254 
ILMN_2115752 MEFV 0.41 2.56E-05 0.254 
ILMN_2379718 RAB24 0.35 2.73E-05 0.259 
ILMN_2092333 GPR141 0.39 2.85E-05 0.264 
ILMN_2058782 IFI27 0.81 2.93E-05 0.268 
ILMN_1739274 PDHB -0.25 3.10E-05 0.275 
ILMN_1713561 C20orf103 0.54 3.11E-05 0.275 
ILMN_1753745 HDDC2 -0.3 3.19E-05 0.276 
ILMN_1696654 IFIT5 0.37 3.24E-05 0.277 
ILMN_1769520 UBE2L6 0.57 3.24E-05 0.277 
ILMN_1658759 PEX19 -0.26 3.24E-05 0.277 
ILMN_1705241 TDRD7 0.44 3.35E-05 0.28 
ILMN_1811823 MED25 0.19 3.35E-05 0.28 
ILMN_3237165 LOC100128164 0.13 3.34E-05 0.28 
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ILMN_2344079 ZGPAT 0.14 3.49E-05 0.288 
ILMN_1772824 WNT5B 0.39 3.57E-05 0.29 
ILMN_1733176 LIMS1 -0.44 3.57E-05 0.29 
ILMN_3246953 FTSJD2 0.31 3.64E-05 0.294 
ILMN_2104696 ERICH1 0.27 3.63E-05 0.294 
ILMN_2198376 PSMA4 0.22 3.70E-05 0.296 
ILMN_1729115 UBE2S 0.22 3.89E-05 0.304 
ILMN_1776723 PHF11 0.34 3.91E-05 0.304 
ILMN_1795704 KIAA0232 -0.09 3.95E-05 0.306 
ILMN_1792305 ZNF318 -0.38 3.97E-05 0.307 
ILMN_1687495 SLC37A1 0.16 4.04E-05 0.31 
ILMN_1812926 ANTXR2 0.51 4.19E-05 0.314 
ILMN_1678422 DHX58 0.65 4.17E-05 0.314 
ILMN_1673649 HYOU1 0.34 4.19E-05 0.314 
ILMN_1731001 ERICH1 0.25 4.26E-05 0.318 
ILMN_1780756 RBM23 0.16 4.30E-05 0.321 
ILMN_1651346 TICAM2 0.32 4.41E-05 0.326 
ILMN_1802151 OSBPL5 0.22 4.45E-05 0.326 
ILMN_1809086 XRN1 0.43 4.44E-05 0.326 
ILMN_2393544 PRMT2 0.27 4.53E-05 0.329 
ILMN_1652525 FAM125B 0.4 4.82E-05 0.34 
ILMN_1803652 C9orf91 0.3 4.84E-05 0.34 
ILMN_1710740 C2 0.13 4.86E-05 0.34 
ILMN_1765547 IRF2 0.27 4.88E-05 0.341 
ILMN_1903568 CR625988 -0.32 4.93E-05 0.341 
ILMN_1789095 BMPR2 0.31 4.96E-05 0.341 
ILMN_1718303 PVRL2 0.33 4.98E-05 0.341 
ILMN_2311826 USP6NL 0.23 5.19E-05 0.346 
ILMN_1684789 CCDC101 0.17 5.20E-05 0.346 
ILMN_1753547 STAT5A 0.49 5.13E-05 0.346 
ILMN_1811171 GPR132 0.44 5.20E-05 0.346 
ILMN_2376108 PSMB9 0.55 5.13E-05 0.346 
ILMN_1795991 C22orf28 0.25 5.11E-05 0.346 
ILMN_2388466 TIA1 0.21 5.12E-05 0.346 
ILMN_3268914 CLEC2D -0.25 5.39E-05 0.354 
ILMN_2112988 NCF1C 0.58 5.45E-05 0.355 
ILMN_2365465 XBP1 0.26 5.43E-05 0.355 
ILMN_2167416 MR1 0.24 5.62E-05 0.361 
ILMN_2339006 KIAA0564 -0.3 5.66E-05 0.361 
ILMN_1802106 APOBEC3G 0.43 5.68E-05 0.361 
ILMN_2415157 ARID5A 0.22 5.81E-05 0.364 
ILMN_2103362 ARHGAP27 0.18 5.97E-05 0.367 
ILMN_1701455 FBXO6 0.37 6.00E-05 0.368 
ILMN_1745356 CXCL9 0.55 6.11E-05 0.371 
ILMN_1750400 C19orf66 0.42 6.17E-05 0.371 
ILMN_2344373 MVP 0.29 6.15E-05 0.371 
ILMN_1719392 FH -0.24 6.31E-05 0.376 
ILMN_1723414 HACL1 -0.21 6.35E-05 0.376 
ILMN_1789955 PNRC1 0.27 6.38E-05 0.376 
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ILMN_1654488 KDM6A 0.28 6.43E-05 0.377 
ILMN_1761820 EDARADD 0.13 6.46E-05 0.377 
ILMN_1695917 C5orf15 0.27 6.54E-05 0.379 
ILMN_1665428 GSDMD 0.44 6.78E-05 0.386 
ILMN_2166524 CCNYL1 0.26 6.76E-05 0.386 
ILMN_1729973 ZC3HAV1 0.68 6.87E-05 0.389 
ILMN_1745397 OAS3 0.82 6.86E-05 0.389 
ILMN_1683678 SPATS2L 0.52 6.96E-05 0.391 
ILMN_1777660 RNF144A 0.16 7.11E-05 0.392 
ILMN_2262044 PARP10 0.5 7.02E-05 0.392 
ILMN_1860051 C20656 0.33 7.30E-05 0.398 
ILMN_1787680 SELS 0.18 7.30E-05 0.398 
ILMN_3199438 X69637 0.23 7.30E-05 0.398 
ILMN_1801307 TNFSF10 0.82 7.29E-05 0.398 
ILMN_1706326 MRPL33 -0.16 7.45E-05 0.402 
ILMN_1774287 CFB 0.99 7.57E-05 0.404 
ILMN_1801766 CCDC109B 0.4 7.56E-05 0.404 
ILMN_1807114 UNC93B1 0.27 7.63E-05 0.404 
ILMN_1694070 FAM114A1 0.11 7.76E-05 0.405 
ILMN_1760727 ANG 0.18 7.79E-05 0.405 
ILMN_1751330 RBCK1 0.33 7.92E-05 0.405 
ILMN_1695432 TPST2 -0.28 7.92E-05 0.405 
ILMN_2300186 DYNLL1 -0.21 7.94E-05 0.406 
ILMN_1691567 GNPDA2 -0.13 8.13E-05 0.407 
ILMN_1781374 TUFT1 0.26 8.14E-05 0.407 
ILMN_1716272 KBTBD8 -0.36 8.23E-05 0.409 
ILMN_1683026 PSMB10 0.23 8.31E-05 0.41 
ILMN_1710844 PARP10 0.44 8.68E-05 0.414 
ILMN_1728349 TMEM63B 0.19 8.50E-05 0.414 
ILMN_1674063 OAS2 0.57 8.74E-05 0.414 
ILMN_1794470 ANKFY1 0.24 8.73E-05 0.414 
ILMN_3243928 DDX60L 0.45 8.42E-05 0.414 
ILMN_1731181 TEX2 -0.23 8.80E-05 0.415 
ILMN_1728073 DENND1A 0.16 8.91E-05 0.416 
ILMN_1897741 CR610863 -0.28 8.97E-05 0.418 
ILMN_1769129 CCL19 0.75 1.00E-04 0.44 
ILMN_1688526 ARL5A -0.23 1.01E-04 0.44 
ILMN_3219806 UNC93B1 0.42 1.01E-04 0.44 
ILMN_1797001 DDX58 0.44 1.03E-04 0.441 
ILMN_1750401 C17orf62 0.27 1.03E-04 0.441 
ILMN_2362581 FNDC3A 0.33 1.03E-04 0.441 
ILMN_1759250 TAP2 0.43 1.02E-04 0.441 
ILMN_1808661 TOMM5 -0.24 1.04E-04 0.441 
ILMN_1678054 TRIM21 0.31 1.05E-04 0.442 
ILMN_2360784 RRBP1 0.24 1.07E-04 0.442 
ILMN_1767934 PCSK5 -0.28 1.07E-04 0.442 
ILMN_1653711 FZD2 0.32 1.08E-04 0.442 
ILMN_1807044 UBAC1 -0.19 1.07E-04 0.442 
ILMN_1678140 HEATR8-TTC4 -0.15 1.08E-04 0.442 
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ILMN_1779324 GZMA 0.14 1.05E-04 0.442 
ILMN_2046896 ESRRA -0.21 1.06E-04 0.442 
ILMN_1795227 DYNLL1 -0.19 1.09E-04 0.446 
ILMN_1682098 PSMA4 0.28 1.10E-04 0.446 
ILMN_2343010 BOLA3 -0.26 1.10E-04 0.446 
ILMN_1662795 CA2 -0.89 1.10E-04 0.447 
ILMN_3239785 CHEK2 0.25 1.10E-04 0.447 
ILMN_1801938 NHS 0.07 1.11E-04 0.447 
ILMN_2329679 TPST2 -0.3 1.12E-04 0.45 
ILMN_2235851 NEURL3 0.48 1.12E-04 0.45 
ILMN_1720083 EHD4 0.21 1.13E-04 0.45 
ILMN_2404665 TRIM5 0.23 1.14E-04 0.452 
ILMN_1776777 ADAR 0.31 1.16E-04 0.453 
ILMN_1676555 TTC26 0.2 1.17E-04 0.456 
ILMN_1695058 SLC38A5 0.13 1.19E-04 0.457 
ILMN_2359627 BCL2L11 0.22 1.19E-04 0.457 
ILMN_2373763 CASP7 0.41 1.20E-04 0.457 
ILMN_1793012 C7orf44 0.14 1.20E-04 0.458 
ILMN_2406313 RBCK1 0.28 1.21E-04 0.46 
ILMN_2045729 WDR12 -0.31 1.22E-04 0.461 
ILMN_1718734 MLLT6 0.24 1.23E-04 0.463 
ILMN_1765851 TRADD 0.28 1.24E-04 0.466 
ILMN_2129877 PARP11 0.22 1.25E-04 0.468 
ILMN_1750079 PURB -0.29 1.26E-04 0.47 
ILMN_1760490 ACVR1 -0.4 1.27E-04 0.47 
ILMN_1745374 IFI35 0.54 1.27E-04 0.47 
ILMN_2312275 SRP54 0.14 1.28E-04 0.47 
ILMN_1739840 LRRC8A -0.18 1.31E-04 0.472 
ILMN_3234831 RPL17 -0.12 1.31E-04 0.472 
ILMN_1688621 C9orf80 -0.18 1.33E-04 0.473 
ILMN_1678862 FUT11 0.09 1.34E-04 0.476 
ILMN_1727315 DENND1A 0.22 1.35E-04 0.477 
ILMN_1750051 FAM123B 0.19 1.36E-04 0.478 
ILMN_1763207 BATF3 0.5 1.36E-04 0.478 
ILMN_1724181 IL15 0.46 1.37E-04 0.479 
ILMN_1804738 MEFV 0.28 1.38E-04 0.481 
ILMN_1664646 NSUN6 0.1 1.38E-04 0.481 
ILMN_2400935 TAGLN 0.07 1.43E-04 0.489 
ILMN_2065783 EXOC2 0.22 1.44E-04 0.491 
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Chapter 4: Conclusions and future perspectives 
   
In this body of work, we set out to experimentally investigate common regulatory variants 
discovered in population-based eQTL studies and rare regulatory variants. The motivation for this 
goal stems from the fact that that the vast majority of GWAS variants are regulatory (Maurano et 
al., 2012). eQTL signals which overlap GWAS signals can help in the interpretation of these 
variants by pointing to a mechanism and gene of action (Battle et al., 2014; Grundberg et al., 2012; 
GTEx Consortium et al., 2017; Lappalainen et al., 2013; Nicolae et al., 2010). If these signals are 
to be understood, identifying the causal variants at eQTLs and the consequences of these regulatory 
variants through experimental validation is essential.  
In chapter 2, we established a method to validate regulatory variants that are found within 
the transcript. While previous studies have tested rare variants’ regulatory effect (Li et al., 2017), 
and saturation mutagenesis of all variants in particular exons (Findlay et al., 2014; 2018), a scalable 
method for testing eQTL variants within the transcript has not previously been developed. 
Additionally, our study is unique in that we establish a control variant distribution with which 
variants genome-wide can be compared. We showed that matched control variants which introduce 
a non-stop codon at the same locus as the variant of interest are not ideal controls. Some of these 
variants have unpredictable effects on gene expression levels and thus result in an artificially large 
control distribution. Instead, we find that a distribution of synonymous variants which are not 
significantly associated with eQTLs is a more appropriate control distribution. By using this 
control distribution, we take into account the background noise involved in the assay and are 
therefore better able to confidently identify causal regulatory variants. 
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A reliable assay which not only identifies causal regulatory variants, but also captures the 
magnitude and direction of effect within the native genomic context has also not existed until now. 
While MPRAs are scalable assays to identify variants which affect expression, they have been 
found to have low directional concordance with population data (Tewhey et al., 2016; van 
Arensbergen et al., 2019), likely due to the removal of the variants from their genomic context by 
introducing them into a reporter vector. It is notable that in this study we did maintain the genomic 
context, allowing us to detect the specific and directional effects of regulatory variants in the 
genome. Additionally, MPRAs are not able to interrogate variants which act by affecting the 
stability of transcripts. 
We demonstrated that the polyclonal assay works particularly well for variants which 
introduce premature stop codons into the transcript. Of the fourteen total stop-gained variants (both 
common GTEx stop-gained and disease gene stop-gained) which were expected to trigger NMD, 
eleven had significant effects on transcript abundance after editing, all in the expected direction. 
Additionally, none of the four disease gene stop-gained variants which were not expected to trigger 
NMD were significant, demonstrating sensitivity and specificity of the assay. The reason for the 
strong success with the stop-gained variants may be because there is a clear cell-type-independent 
mechanism through which the variants act. NMD is a universal pathway present in all cell types, 
whereas other mechanisms through which eQTL variants regulate might be cell-type specific. 
Additionally, NMD effects of rare variants tend to be larger than the relatively small effects of 
eQTL variants.  
When we applied the polyclonal assay to eQTL variants, we found five of the thirteen 
variants to be significant. Importantly, all five of these variants’ effects were in the same direction 
as we saw in GTEx, demonstrating the assay’s ability to capture directional effects of regulatory 
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variants. There are a few possible reasons for why the remaining eQTL variants were not detected 
to a significant level. Perhaps the most likely reason for this shortfall is that the fine mapping fell 
short of identifying the true causal variants at the loci. With a scarcity of validated experimental 
data in the field (a fact that motivated this study), it is hard to assess fine-mapping approaches’ 
ability to distinguish causal variants from those in linkage disequilibrium. When we looked at the 
p-value distributions of the eQTL signals, we observed that many of the variants are in high linkage 
disequilibrium with neighboring variants, which also have highly significant p-values. These 
neighboring significant variants could conceivably be causal and were mis-identified by fine-
mapping. Thus far, fine-mapping approaches have only been tested for efficacy on simulated data 
(Brown et al., 2017; Hormozdiari et al., 2014; Wen et al., 2016), meaning we have little insight 
into how effective they are at identifying causal variants at real eQTLs. In the future, the polyclonal 
assay could be utilized to distinguish between significant variants at a locus and thus test the 
efficacy of fine-mapping approaches.  
However, the non-significant eQTL variants whose effect hovers around zero seem to be 
truly not causal in this cell line.  By investigating the range of effects both across tissues and across 
individuals, we showed that some of these variants might be context-specific and not active in this 
cellular context. Additionally, the possibility of eQTLs reflecting combined effects of multiple 
variants in a haplotype could explain why a single variant does not replicate the effect seen in the 
population.  
Another likely explanation for why we don’t detect every eQTL as significant is that the 
assay is not sensitive enough to detect the very small effects of weak eQTLs. This phenomenon 
can be observed in the three eQTL variants, chr20_3213332_G_A_b38, 
chr17_81294933_T_C_b38 and chr9_133361131_C_T_b38, which are not called as significant 
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but have similar effects to those seen in GTEx. Technical improvements to homologous 
recombination efficiency, which is a major area of research (Aird et al., 2018; Gutschner et al., 
2016; Song et al., 2016), could reduce noise in the assay and make it able to detect these smaller 
effects in the future. 
The success of the polyclonal assay when applied to stop-gained variants in disease-
associated genes demonstrates the applicability of the assay to confirming the causality of potential 
disease-causing variants. The relationship between disease manifestation and position of the 
premature stop codon in the transcript in GLI3 (Furniss et al., 2007) and ROR2 (Ben-Shachar et 
al., 2009) promotes the idea that understanding whether a variant results in NMD or truncated 
protein can provide diagnostic insight into the disease. While the 55 bp NMD cutoff provides a 
guideline for whether a variant triggers NMD or not, this prediction is far from perfect (Rivas et 
al., 2015). Therefore, the polyclonal assay could feasibly be applied to improving diagnostic or 
prognostic information for patients with rare variants of unknown consequence, such as variants 
falling right at the NMD border.  
In some cases, there have been conflicting reports on the mechanism of some disease-
causing stop-gained variants, and this assay could assist in resolving those cases. We showed the 
capacity to do such by demonstrating that the ClinVar variant ROR2 Arg442Ter triggers NMD. 
This variant was found in a patient with Robinow Syndrome and shown experimentally to produce 
truncated protein (Schwarzer et al., 2009). However, the study used an overexpression vector to 
express the two alleles of the variant in cell culture, and thus was perhaps overwhelming the NMD 
machinery and thus producing truncated protein. It appears that in the native genomic context, as 
in our assay, the variant triggers NMD and results in an allele-specific decrease in gene expression 
level. Our result is more consistent with the clinical manifestation of the disease: both parents of 
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the patient are unaffected, suggesting the disease is not caused by a dominant negative effect of 
truncated protein. Similarly, we demonstrated in the assay that ClinVar variant GLI3 Arg792Ter, 
identified in patients with Grieg cephalopolysyndactyly, triggers NMD. An early study 
hypothesized that the variant acted through production of truncated protein (Kalff-Suske et al., 
1999). Another study suggested the variant may be triggering NMD, but their data from allele 
specific expression in a patient line did not support it (Johnston et al., 2005). Finally, a study 
demonstrated allele-specific depletion of the mutation in a patient-derived fibroblast line (Furniss 
et al., 2007), a result which agrees with our findings. The polyclonal assay avoids the need to 
isolate patient-derived cell lines and is thus more scalable and appropriate for testing many variants 
with appropriate controls. 
Furthermore, we see an application of this assay to narrowing down causal variants in 
studies where one may have dozens of possible causal variants, such as in whole exome sequencing 
studies. In such a case, the monoclonal cell line isolation approach is too labor-intensive for this 
number of variants, and has the potential to be confounded by large on- and off-target mutations, 
but a higher throughput method like saturation mutagenesis, currently applicable only to individual 
genes, is laborious and lacks the ability to assay variants across the genome. This polyclonal assay 
is the ideal throughput for identifying causal variants from a list of a few dozen candidate variants 
discovered from a genetic study. Although we did not take this approach in this study, it would be 
feasible to perform the polyclonal assay on a number of potential regulatory variants, sequencing 
mRNA and gDNA from the polyclonal culture, and then take the same polyclonal culture and sort 
monoclonal cell lines for only the variants which demonstrate allele-specific regulatory activity. 
In this approach, the polyclonal assay narrows down the pool of variants to a reasonable number 
for in-depth follow up with functional assays, protein quantification, and other assays. The 
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straight-forward nature of the polyclonal assay makes it easily adoptable in any lab with tissue 
culture facilities and access to a sequencing instrument. 
The assay need not be limited to SNPs associated with gene expression levels. It can easily 
be applied to assessing the effect of indels, by introducing the indel into the homologous template 
instead of a SNP and comparing the presence of the indel in the cDNA versus gDNA. Additionally, 
we see a clear application of the assay to testing whether or not transcript variants affect splicing. 
If applied to splicing, the only modifications to the assay would be to look for splicing changes in 
the amplified region between the reference and alternative alleles. 
In Chapter 3, we sought to experimentally validate a variant which is associated with IRF1 
in cis and many genes in trans under immune stimulation. Trans-eQTLs have been more difficult 
to discover than cis-eQTLs due to multiple testing, false positives and negatives attributed to 
technical confounders and generally smaller effect sizes (Saha and Battle, 2018; Võsa et al., 2018). 
However, there is evidence that trans-eQTLs, which are enriched in enhancers and tend to be more 
tissue-specific (GTEx Consortium et al., 2017), and are even more informative for understanding 
the genetic basis of complex disease (Aguet et al., 2019; Westra et al., 2013). Unlike cis-eQTLs, 
trans-eQTLs have the potential to influence broad cellular networks by regulating the expression 
levels of many genes (Brynedal et al., 2017), and thus can illuminate pathway-level effects of 
genetic variants, which is important for understanding potential disease mechanisms beyond the 
local effects in cis. While there are a few examples of experimental validation of cis-eQTLs (Gupta 
et al., 2017; Soldner et al., 2016; Zhu et al., 2016), there has been almost no validation of trans-
eQTLs. Therefore, detecting and validating trans-eQTLs is of the utmost importance. 
Variants within close proximity to IRF1 have been found through GWAS to be associated 
with immune-related diseases such as Crohn’s Disease (Franke et al., 2010), eczema (Kichaev et 
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al., 2019) and asthma (Demenais et al., 2018; Ferreira et al., 2017). Additionally, variants in IRF1 
and signaling disruption of IRF1 have been implicated in multiple sclerosis (Fortunato et al., 2008; 
Ren et al., 2011), further linking IRF1 to autoimmune disease. Our work provided strong evidence 
of the functional mechanisms of this disease-associated locus. The further mechanism of how the 
IRF1 pathway affects autoimmune disease risk is yet unknown, but since IRF1 induces expression 
of pro-inflammatory cytokines which can induce an inflammatory response in a broad range of 
cell types (Kröger et al., 2002), this is the likely mechanism. Future studies to analyze the variant’s 
effect on cytokine production in an immune cell line or mouse model could further explore the 
physiological and cellular effects of the variant.  
IRF1 is known to be induced by TLR signaling, and in turn induces expression of type-I 
interferons (Miyamoto et al., 1988). However, its role in TLR4 signaling in response to LPS is not 
well characterized beyond the finding that IRF1 is induced in monocytes in response to LPS (Kim-
Hellmuth et al., 2017) and that irf1 knockout mice have increased survival after LPS infection as 
compared to controls (Pan et al., 2013). Our finding that an enhancer variant alters expression of 
IRF1 and a multitude of downstream genes in response to LPS further bolsters the idea that IRF1 
plays a role in LPS response in the innate immune system. 
The correlation between our edited cell lines and the trans-eQTL associations under 
stimulation helps to validate the trans-eQTL association. The eQTL variant can be classified as a 
master regulatory variant, due to its impact on a number of genes involved in immune response. 
Individuals with the variant exhibit increased expression levels of IRF1 and its targets, i.e. an 
increased immune response to stimulus. We discovered the variant in the context of LPS 
stimulation, but the variant could possibly modify IRF1 and its targets in any case where IRF1 is 
upregulated via activation of this enhancer.  The association of the variant in a GWAS for 
   
 96 
inflammatory traits (Ellinghaus et al., 2016) is consistent with this idea, since inflammatory 
disorders are characterized by an overactive inflammatory response. The trans-eQTL could 
feasibly contribute to inflammatory disease by increasing the expression of IRF1 and its targets in 
response to LPS stimulation. 
With the IRF1 locus, we discovered a variant which is not active under baseline but affects 
IRF1 expression under LPS stimulation. This context-dependence lends information as to how the 
variant might influence cellular networks in a physiological context. Immune-response eQTLs 
have been found to be more highly enriched for autoimmune GWAS loci than baseline eQTLs 
(Kim-Hellmuth et al., 2017). This variant might be widely important for immune response in 
humans and would not have been discovered under baseline conditions, emphasizing the 
importance of looking at how regulatory variants impact the transcriptome in a variety of cellular 
contexts.  
Our attempts at validating regulatory variants also demonstrate the challenges involved. 
Isolating monoclonal cell lines, the approach utilized in chapter 3, is time- and resource-
consuming. Additionally, unexpected genetic and epigenetic effects in monoclonal cell lines can 
create undetected noise. In this case, we could not utilize the polyclonal assay to validate the cis 
effect because the top variant is located in an enhancer, not in the gene body, and it would not have 
given us information about the trans effects of the variant. In differential expression analysis 
between clones with deletions at the eQTL variant locus and wildtype clones, as well as in the 
CRISPRi-treated cells, the cis-regulatory signal was not clear, and we failed to detect the trans-
eGenes as significantly differentially expressed genes. It may be that the number of clones of each 
genotype needed to detect the trans-eQTL signal is much higher than the number isolated in this 
study, and in similar studies (Gupta et al., 2017; Soldner et al., 2016; Zhu et al., 2016). Logically, 
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it seems as though you would need many fewer edited cell lines than individuals in eQTL studies 
because you are introducing the mutation into a constant genomic background. However, the 
results from ours and similar studies suggest that the number of clones needed for detecting 
transcriptome effects has been underestimated. In our analysis, we were able to capture the effects 
of CRISRPi and CRISPR perturbations by leveraging the power of analysis of the entire 
transcriptome that allows detection of even small effects.  
In addition to undetected off-target and on-target mutations in these clones (Kosicki et al., 
2018), transformed cell lines are known to have a multitude of chromosomal rearrangements, 
which may vary between individual cells in the cell line (Boone et al., 2014). For future studies 
utilizing the edited monoclonal cell line approach to validate regulatory effects of variants, it is 
imperative to isolate many clones of each genotype. Additionally, more thorough genotyping of 
the targeted locus in wild type and edited clones to detect large insertions or deletions at the 
targeted locus should be considered. This thorough genotyping can be performed using approaches 
such as long-range PCR, as was used in chapter 3 to eliminate one of the clones, or genomic qPCR 
which can be used to quantify the copy number of the genomic region surrounding the variant 
(D'haene et al., 2010). Furthermore, the proper choice of control is important. If a cell line which 
has not undergone editing is used as a control, there is a risk of confounding the results by detecting 
off-target or clone-specific effects in the edited clones instead of the effect of the specific variant. 
Therefore, control cell lines should be chosen from the same set of monoclonal cell lines as the 
edited cell lines, as we did in this study. Since there is generally no shortage of clones which do 
not harbor the desired mutation, isolating a number of these control cell lines is not a challenge, 
although their analysis by RNA-sequencing adds to the cost of these studies.  
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Another consideration to be taken into account when doing these types of validation 
experiments is that studying genetic effects in cell lines will never perfectly capture the effect of a 
variant that is observed in a population. All cell lines have limitations and the genomic 
rearrangements that occur in immortalized cell lines (Boone et al., 2014) no doubt can affect the 
genome and transcriptome of the cells. However, in order to find causality at a population-based 
association signal, experimental validation of the regulatory variant is essential. Additionally, 
eQTL studies, especially trans-eQTL, which are based on correlation in the population, are subject 
to false positives and negatives. Therefore, association studies and experimental validation studies 
provide complementary information on the effects of genetic variants.  
Over the past fifteen years, researchers have discovered tens of thousands of GWAS 
associations to an extensive array of human traits. However, identifying a genetic signal is just the 
beginning of the story.  The causal variant, the gene of action, and the mechanism of action of the 
association are often unclear. Therefore, our ability to identify and prove causality of regulatory 
variants in the population is of the utmost importance to the field of genomics. This elucidation is 
crucial for understanding the mechanism of variants that cause disease, and therefore discovering 
therapeutic targets. Despite the drawbacks associated with the different methods applied to 
functional genomics, further optimization and development in this field is necessary. This 
development is needed in order to expand our understanding of how the genetic variation between 
us humans defines the combination of traits that makes each of us unique.   
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